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ABSTRACT 
Frailty is regarded as the most problematic consequence of aging. Whilst there is no precise 
definition for frailty, most clinicians agree that patients who are frail are vulnerable to poor health. 
Frailty can be conceptualised as a syndrome with a set of symptoms and signs that are measured to 
give a categorical classification of frailty as described by Fried and colleagues. Alternatively, frailty 
can be considered as a state, where deficits in health across multiple organ systems accumulate over 
time. These deficits are summated to give a continuous measure of frailty called the frailty index 
(FI).  
Patients with chronic kidney disease (CKD) are at risk of frailty. CKD has effects in multiple 
systems and it leads to accelerated manifestation of frailty, especially in those who are on dialysis. 
The Fried approach to frailty assessment has been applied in numerous settings of patients with 
CKD. However, there are limitations of the Fried approach especially when the prevalence of frailty 
is high, and a more precise measure is needed of the severity of frailty in an individual. 
The thesis begins with a systematic review of frailty in patients with CKD. It focuses on how frailty 
is assessed, including the Fried approach and other assessment methods; differences in frailty 
between dialysis and pre-dialysis patients; and how frailty changes across the spectrum of severity 
in kidney function. The systematic review yielded 37 articles encompassing 53,000 patients with 
CKD. The most common method of frailty assessment was the Fried approach (n=27 articles, 73%). 
The prevalence of frailty ranged between 7% in a population of pre-dialysis patients with CKD to 
73% in patients on dialysis. There was considerable heterogeneity in how the studies defined the 
Fried phenotype and this impacted on the reported prevalence of frailty. Regardless of the method 
of assessment, frailty was associated with an increased risk of mortality and hospitalization.  
The systematic review highlighted gaps in the current evidence, especially in better delineating risk 
amongst patients on dialysis where the prevalence of frailty may be high. This leads to the next 
chapter of the thesis, a prospective study of the Frailty Index in CKD (FI-CKD). The aim of the 
study was to investigate the frailty index (FI) in outpatients with pre-dialysis and dialysis dependent 
CKD. Associations between FI and kidney function were explored as well as the relationship 
between FI and change in kidney function, mortality and hospitalization after twelve months of 
follow up. Amongst 314 patients, the mean FI was 0.29 (SD 0.13) corresponding to a clinical 
description of mild to moderate frailty. FI was associated with an increased risk of mortality (OR: 
1.8; 95% CI 1.77 – 2.44) and hospitalization (OR 1.3 95% CI 1.06-1.5). Patients with a higher CKD 
stage were significantly more likely to have a higher FI. However, there was no significant 
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differences in the average FI between dialysis and pre-dialysis patients, perhaps due to the limited 
number of patients on dialysis (n=86, 27%) or due to selection bias.   
The final chapter reviews the implications of the prospective study for clinical practice. FI may be 
incorporated into electronic medical records to provide more contemporaneous support for clinical 
decision making. The studies described in this thesis have provided the basis for a longitudinal 
investigation of frailty in patients with end stage kidney disease and exploring changes in FI with 
dialysis initiation versus conservative management.    
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CHAPTER 1: INTRODUCTION 
1.1 Defining Frailty  
Frailty is a state of increased vulnerability to health problems. There are two acknowledged 
conceptualisations of the term, which have resulted in different approaches to its measurement (1). 
Firstly, frailty can be thought of as a syndrome with sarcopenia as the key pathophysiological 
feature (2): this facilitates the measurement of frailty using a specific set of signs and symptoms that 
are measured to classify patients who are frail or not. The second approach views frailty as a state 
of deficit accumulation that begins at the cellular level and leads to a loss of redundancy in organ 
systems (3-5); here, frailty is quantified by counting deficits across multiple systems. This provides 
a continuous variable that not only describes if a patient is frail or not but also the severity of the 
frailty. Patients who are frail, regardless of how it is measured, experience a decline in physical 
function and are at an increased risk of adverse health outcomes. Although there is a strong positive 
correlation between frailty and chronological age, patients with chronic diseases also appear to be 
predisposed to frailty (6).  Patients with chronic kidney disease (CKD) are at a higher risk of frailty 
and subsequent adverse health outcomes.  
 
1.2 Demographics 
The assessment of frailty is increasingly becoming important because population aging means more 
primary and tertiary health care providers are involved in geriatric care. Recent data from the 
Australian Bureau of Statistics demonstrate that the proportion of patients aged above 65 years has 
increased from 12% to 15.3% between the period of 1996 to 2016 (7). In the same period, the 
proportion of patients aged above 85 years has almost doubled from 1.1% to 2.0% (7).  Due to 
decrease in fertility rates and improved survival rates, the rate of population aging in Australia is 
projected to increase further into the future (7). This has implications for the provision of health 
care, housing, the size of the working population and the need for skilled labour (7). New Zealand 
and other developed nations including Japan, Canada and the United States, are experiencing 
similar changes in population aging.  
CKD is prevalent amongst older Australians with 42.2% of individuals above 75 years of age 
having an indicator of CKD (8). The AusDiab study, conducted in 42 randomly selected census 
localities across Australia, showed that increasing age was the strongest risk factor for the presence 
of CKD even after multi-variate analysis (9). The prevalence of end stage kidney disease requiring 
treatment is projected to increase to 31, 589 individuals by 2020 with the greatest rise occurring in 
those above 75 years of age (10). Furthermore, the survival of patients on dialysis is improving 
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(11). A recent observational study showed a 25% reduction in adjusted mortality rate with dialysis 
inception in Australia and New Zealand between years 2008-2012 compared to 1998-2002 (11). 
Patients on dialysis are living longer and the age of commencement of dialysis is increasing. Thus, 
the care of older individuals with CKD will become increasingly important.  The most common 
aetiology of CKD requiring renal replacement therapy in Australia is diabetes followed by primary 
glomerulonephritis and hypertension (12). There is a similar spectrum of CKD in patients in New 
Zealand, however, primary glomerulonephritis is more common (12).  
 
1.3 Pathophysiology 
Aging can be viewed as the accumulation of damage to multiple systems at the cellular and 
molecular level (13). This is dependent on the maintenance and repair systems which are influenced 
by genetics and epigenetics and ultimately results in the phenotype of aging. Many organ systems 
have redundancy that confers a certain resilience against insults such as disease. However, in 
patients who are frail, there is loss of redundancy, meaning that even trivial insults such as a change 
in medication, urinary tract infection or admission to hospital can result in instability and falls, 
delirium and disability (13). The accumulation of deficits in multiple systems leads to a reduction in 
redundancy and leads to the phenotype of the frail patient.  
Frailty has been studied in relation to changes in multiple organ systems including the brain, 
immune system, skeletal system and hormonal control. In the brain, aging is associated with loss of 
function of hippocampal neurons, which are involved in memory and potentiation of microglial 
cells which may cause neuronal injury and are implicated in delirium (13). There are changes to the 
innate and adaptive immune system resulting in a blunting of response to an acute stimulus (13). 
However, following a stimulus there is persistence of a low grade inflammatory response even after 
removal of the stimulus. This is mitigated by multiple cytokines including interleukin-6 (IL-6) and 
tumour necrosis factor-alpha (TNF-alpha), which contribute to muscle catabolism, loss of adiposity 
and anorexia (13). Changes to the endocrine system in frailty include a decrease in IGF-1 levels, 
decrease in the sex hormones including testosterone and oestrogen and a rise in cortisol levels (13). 
The net effect of the hormonal changes and pro-inflammatory cytokine milieu is that there is a 
change in the balance between muscle formation and destruction towards catabolism. This is 
thought to result in the manifestation of sarcopenia, which is a key contributor to frailty (13). 
Aging also affects kidney function.  Firstly, after the age of 30, there is progressive replacement of 
glomeruli with fibrous tissue, known as glomerulosclerosis (14). In the afferent and efferent 
arterioles of the nephrons there is intimal thickening, but the tunica media atrophy, which means 
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there is blunting of the response to autonomic stimuli (such as changes in blood pressure) (14). Loss 
of juxtamedullary nephrons results in direct channels being formed between afferent and efferent 
arterioles resulting in aglomerular circulation (bypassing the glomerulus) (14). Renal tubules 
undergo fatty degeneration and there is thickening of the glomerular basement membrane (14). 
Therefore, there is a decline in glomerular filtration with age and a reduction in the ability to 
reabsorb sodium in the distal tubules (14).  
Senile changes in renal function are inevitable with ageing. However, there are differences between 
patients with CKD and these senile changes. Healthy older individuals have intact proximal tubular 
function, no changes to erythropoietin levels, a normal urine analysis and intact fractional excretion 
of urea, calcium, magnesium, phosphorus and potassium (14). 
The relationship between kidney disease and frailty is not completely understood.  Studies show 
that inflammation is associated with frailty in many chronic diseases and this suggests a ‘shared 
pathophysiology’ of frailty (3). Shilkpak et al demonstrated that there are raised levels of pro-
inflammatory cytokines in CKD patients (15). However, further research is needed to investigate 
the causal relationship between inflammation and frailty specifically in patients with CKD.  
 
1.4 Relationship between Frailty and CKD 
The prevalence of frailty ranges between 7% in patients with pre-dialysis CKD to 73% in a cohort 
of patients on haemodialysis (16, 17). Frailty is associated with an increased risk of death, 
hospitalization and falls in patients with CKD (18). The relationship between frailty and CKD 
depends on the severity of kidney failure, demographics and co-morbidities of the patient. The close 
association of frailty and adverse health outcome reinforces why frailty assessment is an important 
consideration in the care of patients with CKD. The following systematic review will explore the 
relationship between frailty and CKD in more detail. 
 
1.5 Frailty Assessment  
This section addresses the question of how frailty can be identified and assessed in patients with 
CKD. Fried et al described a phenotype for frailty based on a secondary analysis of patients in the 
Cardiovascular health study (2). The Fried approach proposes that frailty is a syndrome with 
sarcopenia and age-related decline in physical function as the key pathophysiological features (2). It 
describes a phenotype of frailty based on the presence of three or more of the following criteria: 
slowness measured with gait speed; weakness measured with grip strength; weight loss of more 
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than 10 pounds in 12 months; low physical activity and exhaustion measured using questionnaires 
(2). The Fried approach is well validated in a number of different settings of patients with chronic 
diseases including the CKD population (6). It is a useful method of screening for frailty and it has 
been shown to be predictive of health outcomes (13).  
However, there are limitations to the Fried approach frailty assessment amongst CKD patients. 
Firstly, the Fried approach categorizes patients into those who are frail and those who are not. This 
can be problematic in populations where the prevalence of frailty is high because the dichotomous 
categorization of frailty using the Fried approach makes it less useful as a predictor of adverse 
outcomes in CKD patients. Furthermore, cognitive impairment and emotional well- being, 
important factors contributing to disability and functional status, are not assessed by the Fried 
phenotype (13). The criteria for frailty require performance-based measurements of gait speed and 
grip strength which may be difficult to apply in some clinical settings and larger cohorts of patients. 
Furthermore, the method by which the criteria are defined is subject to interpretation and this may 
alter the reported prevalence of frailty in a given study population (19).   
The frailty index (FI) is an alternative method of frailty assessment. This approach conceptualises 
frailty as a state of deficit accumulation. These deficits originate at the cellular and molecular level 
and decrease redundancy in organ systems, which lead to an increased vulnerability to stressors. 
The FI approach identifies deficits in health which are equally weighted to calculate a score. 
Deficits are variables which are biologically sensible, accumulate with age and do not saturate too 
early (13).  This typically includes the presence of disease, activities of daily living, disability, 
emotional state and cognition. It is not the type of deficit that is important but the number of deficits 
in determining the level of frailty (13). The FI has been shown to correlate with an increased risk of 
death and institutionalisation in the Canadian Study of Health and Aging (20).  It is well validated 
and has been applied in many different settings.  
Use of the FI has advantages over the Fried approach in CKD patients. Frailty can be quantified as a 
continuous variable, which is more useful in attributing risk especially amongst the dialysis 
population where the prevalence of frailty is high. Furthermore, FI does not rely on performance- 
based data, which is advantageous in the assessment of frailty in larger cohorts.  
Disadvantages of FI are related to its complexity with some models having as many as 90 variables. 
Collecting the information to complete the FI takes time and resources, which may not be available 
in certain clinical settings. A categorical approach to frailty is also more easily understood by 
clinicians and patients rather than a continuous variable without context. Finally, the accuracy of 
16 
any diagnostic tool relies on the quality of data that is inserted into the tool. Recall bias and 
information bias has the potential to reduce the validity of the FI.  
There are several approaches that have been applied to overcome the disadvantages of the FI. 
Firstly, an abbreviated version of the FI with 58 variables has been applied to an outpatient setting 
of patients with CKD in a prior feasibility study (21). This took on average 10 minutes to complete 
and showed good internal validity when compared with the Fried Approach. Furthermore, the FI-
CKD assessment form used in the pilot study has predominantly binary variables that limit 
subjectivity and bias influencing the accuracy of the tool. The FI correlates well with the Clinical 
Frailty Scale (r=0.8) and the FI can be divided into categories with clinical descriptors (such as 
mild, moderate or severe frailty) according to prior work performed by Rockwood and colleagues 
(22). For instance, a cut-off score of 0.25 has been used as the border between fitness and mild 
frailty (22).  
This thesis will continue with a systematic review that examines the current evidence surrounding 
frailty in patients with CKD.  It explores the differences in frailty assessment; prevalence of frailty 
in patients with pre-dialysis and dialysis CKD; the relationship between frailty and changes in 
kidney function estimated with GFR; and the association of frailty in adverse health comes in 
patients with CKD.  The systematic review leads to the prospective study of the Frailty Index in 
Chronic Kidney Disease. The aim of this study is to investigate the FI and the relationship with 
dialysis and changes in kidney function estimated with glomerular filtration rate (GFR). The 
methods of the prospective study including aims, settings, data collection, analysis and ethics will 
be presented. The thesis will present the results and critically analyse the findings in the discussion. 
Finally, the thesis concludes by examining how the research contributes to current and future 
practice.   
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CHAPTER 2: SYSTEMATIC REVIEW 
2.1 Introduction 
There has been great interest in exploring frailty in patients with CKD. Previous literature has 
shown that frailty correlates with adverse health outcomes including an increased risk of mortality, 
hospitalization and falls in patients with CKD (18). Frailty is also a predictor of adverse outcomes 
in patients with kidney transplantation (23).   
A previous systematic review (studies published to 2012) explored frailty in pre-dialysis patients 
and showed an association between frailty and CKD (18). Here, we update and expand this 
evidence, by including patients on dialysis as well as kidney transplant recipients. The aims of the 
systematic review were to explore how frailty is measured in patients with CKD, evaluate the 
relationship between frailty and severity of kidney failure and assess whether it predicts outcomes 
such as mortality and hospitalization. Potential gaps in the available literature and avenues for 
future research will be explored in the prospective study of the FI in patients with CKD (Chapter 3) 
and the conclusions (Chapter 4).  
The systematic review has been published in the journal Geriatrics and Gerontology (24). The full 
review can be found in Appendix 1. For the purposes of the thesis, the systematic review has been 
up dated to include articles published till the 1st November 2017.  
 
 
2.2 Methods 
Search Strategy 
The following search terms were used to identify articles that assessed frailty in patients with CKD:  
‘Chronic kidney disease’ OR ‘kidney disease’ OR ‘Renal Insufficiency’ OR ‘dialysis’ OR ‘kidney 
failure’ OR ‘renal failure’ AND ‘frailty’. 
The focus of this review was on assessment of frailty status. Thus, we did not broaden the search 
criteria for frailty to include geriatric or functional assessments. The literature search was conducted 
using online databases including Pubmed, Medline, Web of science and Cochrane libraries. The 
reference lists of key papers were also examined for articles of relevance. 
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Selection Criteria 
Inclusion criteria for the systematic review were primary research articles that analysed the 
prevalence of, or relationship between, frailty and CKD.  All studies investigating frailty in dialysis, 
pre-dialysis and kidney transplant recipients published before 1st November 2017 were eligible for 
inclusion. Articles were excluded if they were not available in the English language. Where there 
were articles that involved different analyses on the same study population, the article that best 
answered the aims of the systematic review was selected for analysis. 
 
Data Analysis 
Two independent reviewers examined the abstracts for relevance to the study criteria. Where there 
was a difference of opinion about inclusion of the study, a third reviewer was consulted. 
A data extraction table was created which included information about the demographics of the study 
population, the sample size, method of frailty assessment, CKD measurement and outcome 
variables such as mortality rates and hospitalization. 
Each article in the systematic review was assessed for quality using the Epidemiological Appraisal 
Instrument (EAI). The EAI, developed by Genaidy and colleagues, provides a systematic appraisal 
of study quality across the domains of sample selection, exposures and outcomes, statistical analysis 
and adjustment for co-variates and confounders (25). Each domain was scored out of 2, and the 
average across the domains was expressed as the overall EAI score. The closer the score to 2 the 
better the article. 
Due to the significant heterogeneity in the sample populations, method of frailty assessment, and 
CKD measurement a meta-analysis was not performed. 
 
 
2.3 Results 
 
The literature search yielded 586 articles. Sixty articles met the inclusion criteria and were selected 
for full text review. After the full text review a further 23 studies were excluded from further 
analysis for the following reasons: article did not measure frailty in the study population (n=4); not 
available in English (n=3); did not measure frailty in a CKD population (n=4); repeated analyses on 
the same study population (n=9); two article whose results were not available for the systematic 
review; one further article was excluded because of insufficient quality and lack of generalizability 
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of the results to populations outside that study setting.   This resulted in 37 studies that were 
included as part of the systematic review (Figure 1). Overall, there were 19 studies (51%) which 
were designed as primary prospective analyses of frailty in CKD. The remaining 18 studies (49%) 
were secondary analyses of established cohorts not originally sampled for examining frailty. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Systematic Review: Study selection 
586 titles screened after 
literature search 
60 full text articles 
assessed for eligibility  
526 articles 
excluded 
for not 
meeting the 
inclusion 
criteria 
37 articles included into 
systematic review 
23 articles excluded 
following full text review for 
replicated analysis or the 
same study cohort or 
methodological aspects 
that disagreed with the 
inclusion criteria (see 
Appendix 1 for details of 
the excluded studies) 
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Demographics of the Study Population 
There were an equal number of studies included in this systematic review that explored frailty in 
dialysis and pre-dialysis patients with CKD (n=17, 46%), whilst three studies were performed in 
patients who had received kidney transplantation. These studies examined frailty in a total of 52 798 
participants with CKD (84% in pre-dialysis patients and 16% in dialysis patients). The study 
characteristics and population demographics are reported in Tables 1 and 2. 
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Table 1 Systematic Review: Pre-dialysis Patients 
 
Reference Study 
Characteristics 
Study 
Population 
Primary Outcome Study Design EAI Frailty 
assessment 
GFR estimation 
and Average GFR 
Frailty 
Prevalenc
e 
Shlipak et al 
2004 (26) 
N = 648 
%female= 39 
Mean age = 76 
years 
Cardiovascul
ar Health 
Study 
(enrolment) 
USA 
Investigate the prevalence and 
association of CKD with frailty and 
disability 
 
Secondary analysis of 
an established cohort. 
 
1.57 Fried CrCl 
41mLs/min 
15% 
Dalrymple 
et al 2013 
(27) 
N = 4150 
%female = 59 
Mean age = 75 
years 
Cardiovascul
ar Health 
Study (3 year 
review) 
USA 
Examined the prevalence and 
development of frailty in patients 
with incident CKD 
Secondary analysis of 
an established cohort 
 
 
1.67 Fried Cystatin C/CrCl 
73mLs/min 
(median GFR) 
9.7% 
Roshanrava
n et al 2012 
(28) 
N = 336 
%female = 19 
Mean age = 59 
years (+/- 13) 
 
Pre-dialysis 
CKD stages 
1-4 – 
Outpatients 
USA 
Prevalence and association of CKD 
with frailty. Measured outcomes 
including mortality and progression 
to dialysis 
 
Primary prospective 
study 
1.76 Fried Cystatin C 
51mLs/min 
14% 
Wilhelm-
Leen et al 
2009 (29) 
N = 10 256 
%female = 53 
Mean age = 50 
years (+/- 1.3) 
National 
Health and 
Nutrition 
Evaluation 
Survey 
USA 
Correlation of frailty with CKD and 
mediators of this interaction 
 
Secondary analysis of 
an established cohort. 
 
 
1.81 
 
Fried CrCl 
106.21mLs/min 
(includes 
controls) 
7.9% 
Hart et al 
2013 (30) 
N = 1602 
%female = 0 
Mean age = 74 
years (+/- 5.9) 
Osteoporotic 
fractures in 
men Study 
USA 
Association of frailty with CKD 
 
 
Secondary analysis of 
an established cohort 
 
 
1.67 Fried Cystatin C/CrCl 
Mean GFR not 
published 
Not 
published 
Mansur et al 
2014 (31) 
N = 61 
%female = 41 
Pre dialysis 
CKD patients 
Brazil 
Association between frailty, CKD 
and QOL in pre-dialysis patients. 
 
Primary prospective 
study 
1.19 Modified 
Fried 
CrCl 
27mLs/min 
42.6% 
22 
Mean age = 61 
years (+/- 11.5) 
 
Reese RP et 
al 2013 (16) 
N = 1111 
%female = 47 
Median age = 
65 years (+/- 8) 
Chronic renal 
insufficiency 
cohort 
USA 
Association between CKD severity 
and frailty and risk factors for 
frailty. 
 
Secondary analysis of 
an established cohort 
 
 
1.86 Fried CrCl 
49mLs/min 
(median GFR) 
7% 
Yamada et 
al 2013 (32) 
N = 8063 
%female = 62 
Mean age = 81 
years (+/- 7.4) 
J-MACC 
study – 
Community 
dwelling 
individuals 
Japan 
Risk of requiring long-term care 
insurance in frail patients with CKD 
 
Secondary analysis of 
an established cohort 
 
 
1.52 Frailty 
Check List 
CrCl 
Not published 
Not 
published 
McAdams 
De-Marco 
et al 2013 
(23) 
N = 383 
%female = 40 
Mean age = 54 
years (+/- 13.9) 
Renal 
transplant 
recipients 
USA 
Frailty as a risk factor for early 
hospital readmission post kidney 
transplant 
 
Primary prospective 
study 
1.76 Fried No GFR 
estimation 
18.8% 
Garonzik-
Wang et al 
2012 (33) 
N = 183 
%female = 36 
Mean age = 53 
years (+/-14) 
Renal 
transplant 
recipients 
USA 
Association between frailty and 
delayed graft function in renal 
transplant recipients 
 
Primary prospective 
study 
1.52 Fried No GFR 
estimation 
25% 
McAdams 
De-Marco 
et al 2015 
(34) 
N = 349 
%female = 38.1 
Mean age = 
53.3 (+/- 14.2) 
years 
Renal 
transplant 
recipients 
USA 
The natural trajectory of frailty 
before and after kidney 
transplantation. 
 
Primary prospective 
study 
1.67 Fried No GFR 
estimation 
19.8% (at 
baseline) 
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Rodriguez et 
al 2014 (35) 
N = 56 
%female = 48.2 
Mean age = 79 
(+/- 5) years 
Pre-dialysis 
patients 
Spain 
 
Exploring factors that influenced the 
decision for conservative care 
versus dialysis in older patients with 
Stage 4-5 CKD. 
 
Primary prospective 
study 
1.57 Fried CrCl 
16mLs/min 
0% 
Lee et al 
2015 (36) 
N = 168 
%female = 37 
Mean age = 
65.9 years 
Pre-dialysis 
patients 
Korea 
Examine the prevalence of frailty 
and its influence on quality of life 
 
Primary prospective 
study 
1.67 Fried CrCl 
41.1mLs/min 
37.5% 
Montesanto 
et al 2014 
(37) 
N = 1038 
%female = 53.2 
Mean age = 
83.4 years 
Pre-dialysis 
patients 
Italy 
The relationship between frailty, 
GFR estimating using BIS1 
equation and mortality. 
Secondary analysis of 
an established cohort 
1.86 Population 
based 
approach 
CrCl 
53mLs/min 
48.3% 
Meulendijks 
et al 2015 
(38) 
 
N = 63 
%female = 35 
Median age = 
75 years 
Pre-dialysis 
patients 
Netherlands 
Evaluation of whether the 
Groningen Frailty Index can 
distinguish between fitter patients 
who may benefit from dialysis from 
frailer patients in need of geriatric 
assessment. 
Primary prospective 
study 
1.48 Groningen 
Frailty Index 
CrCl 
16mLs/min 
32% 
Hubbard et 
al 2015 (39) 
N = 110 
%female = 46.4 
Mean age = 
65.2 (+/- 14.6) 
years 
Pre-dialysis 
patients 
Australia 
Pilot study investigating the 
feasibility of using the frailty index 
in patients with pre-dialysis chronic 
kidney disease. 
Cross sectional analysis of frailty 
Primary prospective 
study. 
1.76 Frailty index NA Mean FI = 
0.25 
Delgado et 
al 2015 (40) 
N = 812 
%female = 39.5 
Median age = 
52 years (42-61 
years IQR) 
MDRD 
Pre-dialysis 
patients 
USA 
Investigation of self-reported frailty 
and its association with GFR and 
mortality 
Prospective cohort study 
Secondary analysis of 
an established cohort 
1.67 Modified 
Fried 
CrCl 
Iodine 145-
iothalamate 
clearance 
33.1mLs/min 
16% 
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Pugh et al 
2016 (41) 
N = 283 
%female = 44 
Median age = 
74 (63-81 years 
IQR) 
Pre-dialysis 
patients 
UK 
Relationship between frailty and co-
morbidity with the risk of mortality 
in elderly patients referred to an 
outpatient chronic kidney disease 
clinic. 
Primary prospective 
study 
1.48 Clinical 
Frailty Scale 
CrCl 
16mLs/min 
 
33% 
Ballew et al 
2017 (42) 
N = 4987 
%female = 56 
Mean age = 
75.6 years 
Pre-dialysis 
patients 
(ARIC study) 
USA 
Evaluate the relationship between 
frailty, kidney function estimated 
with cystatin C and polypharmacy 
Secondary analysis of 
an established cohort 
1.81 Fried 
phenotype 
Cystatic C 
61mLs/min 
 
6.8% 
Lee et al 
2016 (43) 
N = 9606 
%female = 52.4 
Mean age = 
73.6 (+/- 5.5) 
years 
Pre-dialysis 
patients 
Japan 
 
Investigate the association between 
frailty, kidney function, diabetes 
and hypertension in pre-dialysis 
patients in a Japanese community.  
Secondary analysis of 
an established cohort 
1.62 Modified 
Fried 
Phenotype 
CrCl 
67.4 mls/min 
9.2% 
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Table 2 Systematic Review: Dialysis Patients 
 
Study Study 
Characteristics 
Study Population Primary Outcome Study Design EAI Frailty 
Assessment 
Prevalence 
of frailty 
Bao 2012 et al 
(17) 
N = 1576 
%female = 45 
Mean age = 59.6 
years 
Comprehensive Dialysis 
Study 
HD% = 89.3 
USA 
Frailty prevalence dialysis cohort. 
GFR at dialysis initiation and its 
relationship with frailty 
Secondary analysis 
of an established 
cohort 
1.62 Modified Fried 73% 
McAdams-
DeMarco et al 
2013 (44) 
N = 146 
%female = 47 
Mean age = 61 
years (+/- 13.6) 
Single haemodialysis 
centre 
HD% = 100 
USA 
Prevalence of frailty and outcome 
assessment 
Primary 
prospective study 
1.67 Fried 41.8% 
Delgado et al 
2013 (45) 
N = 80 
%female = 37 
Mean age = 55 
years (+/- 13) 
Nandrolone and Exercise 
Study 
HD% = 100 
USA 
A comparison of function based frailty 
assessment and performance based 
tests. Body composition and frailty 
status. 
Secondary analysis 
of an established 
cohort 
1.19 Modified Fried: 
Performance 
based and 
Function Based 
Criteria 
59% 
(performan
ce based) 
Painter et al 
2013 (19) 
N = 188 
%female = 56 
Mean age = 54.4 
(+/- 16) years 
Renal Exercise 
Demonstration Study 
HD% = 100 
USA 
Analysis of two methods of applying 
the Fried phenotype for frailty: 
questionnaire based physical function 
vs measurement 
Secondary analysis 
of an established 
cohort 
1.81 Fried 24% 
(measured 
physical 
function) 
Johansen et al 
2007 (46) 
N = 2275 
%female = 47 
Mean age = 58 
years (+/- 16) 
Dialysis 
Morbidity/Mortality 
Study 
HD% = 51.9 
USA 
Investigation of the prevalence and 
predictors of frailty amongst dialysis 
patients and correlation with adverse 
health outcomes. 
Prospective cohort study 
Secondary analysis 
of an established 
cohort 
1.71 Modified Fried 68% 
Kutner et al 
2014 (47) 
N = 742 
%female = 40.6 
Mean age = 57 
years (+/- 14.1) 
ACTIVE/ADIPOSE 
Study 
HD% = 100 
USA 
Frailty and its association with ADL 
difficulties 
Secondary analysis 
of an established 
cohort 
1.71 Fried 14% 
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McAdams-
DeMarco et al 
2013 (48) 
N = 95 
%female = 46 
Mean age = 61 
years (+/- 12.6) 
Single dialysis centre 
HD% = 100 
USA 
Association of frailty with risk of falls 
in patients with ESKD 
Primary 
prospective study 
1.71 Fried 46.3% 
Orlandi et al 
2014 (49) 
N = 60 
%female = 30 
Mean age = 71 
years (+/- 6.9) 
Single dialysis centre 
HD% = 100 
Brazil 
Assessment of frailty in elderly 
patients undergoing dialysis 
Primary 
prospective study 
1.10 Edmonton 
Frailty scale 
38% 
Salter et al 
2015 (50) 
 
N = 146 
%female = 46.6 
Mean age = 61 
years 
Single dialysis centre 
HD% = 100 
USA 
Comparison between measured frailty 
and clinician perceived frailty 
Primary 
prospective study 
1.71 Fried 41.7% 
Chao et al 2015 
(51) 
N = 46 
%female = 53 
Mean age = 67.3 
(+/- 11.9) years 
Single dialysis centre 
HD% = 100 
Taiwan 
 
Exploring frailty in a rural dialysis 
centre in Taipei and comparison 
between different self-reported 
measures of Frailty. 
Primary 
prospective study 
1.52 FRAIL scale 
amongst others. 
19.6% 
Alfaadhel et al 
2015 (52) 
N = 390 
%female = 33 
Mean age = 63 
years (+/- 15) 
Single dialysis centre 
HD% = 100 
USA 
Assessed whether the clinicians 
perception of frailty correlated with 
outcomes in a population of patients 
on dialysis. 
Primary 
prospective study 
1.81 Clinical frailty 
scale 
26% 
Iyasere et al 
2016 (53) 
N = 251 
%female = 40.7 
Median age = 76 
(70-81 years 
IQR) 
Single Dialysis Centre 
HD% = 48.6 
UK 
Comparison of frailty and quality of 
life between patients on haemodialysis 
with those on peritoneal dialysis. 
Cross sectional analysis 
Primary 
prospective study 
1.57 Clinical frailty 
scale 
47.4% 
(overall) 
McAdams- 
DeMarco et al 
2015 (54) 
N = 324 
%female = 43.5 
Mean age = 54.8  
years (+/- 13.3) 
Predictors of arrhythmic 
and cardiovascular risk 
in ESKD Study. 
HD% = 100 
USA 
Investigated the relationship between 
frailty and cognition both at base line 
and at one year of follow up. 
Prospective cohort study 
Secondary analysis 
of an established 
cohort 
1.76 Fried 34% 
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Drost et al 
2016 (55) 
N = 95 
%female = 43 
Mean age = 65.2 
years (+/- 12) 
Single dialysis centre 
HD% = 44 
Netherlands 
Comparison between prevalence of 
frailty assessed using the frailty index 
versus the Fried Frailty Phenotype. 
Cross sectional analysis 
Primary 
prospective Study 
1.76 Fried and 
Frailty Index 
36.8% 
(measured 
using FI) 
Ng et al 2016 
(56) 
N = 193 
%female = 49.7 
Mean age = 60.6 
years (+/- 12.1) 
Single centre 
HD% = 0 
PD% = 100 
China 
Investigating frailty in patients on PD 
and its relationship with outcomes 
including mortality, hospitalization 
and technique survival 
Prospective Study 1.71 Frailty 
questionnaire 
69.4% 
Bancu et al 
2017 (57) 
N = 320 
%female = 40.6 
Mean age = 70.3 
years (+/- 14 
years) 
Three dialysis centres 
HD% = 100 
Spain 
Pattern of frailty amongst dialysis 
patients, predictors of frailty and 
outcomes including mortality and 
hospitalization 
Retrospective 
observational 
study 
1.76 Fried phenotype 39% 
Kang et al 2017 
(58) 
N = 1616 
%female = 44.1 
Mean age = 55.9 
years 
Multicentre 
HD% = 77.4 
Korea 
Evaluating differences between frailty, 
quality of life and disability between 
patients on haemodialysis and 
peritoneal dialysis.  
Retrospective 
analysis of an 
established cohort 
1.76 
 
Modified Fried 
phenotype 
34.6% (no 
difference 
PD vs HD) 
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Critical Appraisal of Quality 
The average EAI score for the studies was 1.64 (Standard deviation – 0.18). The individual scores 
for each article are reported in Table 1 and 2. Overall, the articles performed well in describing the 
aims and defining the exposure and outcome variables. However, most articles did not publish 
sample size calculations, participation rates or account for subjects lost to follow up – these criteria 
were three lowest achieved amongst those of the EAI. 
 
Method of Frailty Assessment 
Most of the studies classified frailty using the Fried phenotype (n=27, 73%). However, there were 
variations in the interpretation of the five characteristics of frailty compared to the original 
definitions stipulated by Fried et al (Table 3) (2). 
Estimation of physical activity and exhaustion showed the most heterogeneity between the studies. 
The most common methods of physical activity assessment were patient self-report (n=11, 41%), 
estimation of kilocalories (n=9, 33%), and questionnaire based assessment (n=7). Exhaustion was 
determined most frequently by patient self-report (n=13, 48%), Short-Form 36 (SF-36) vitality 
score (n=7) and the Centre for Epidemiological Studies Depression Scale (n=6). Grip strength was 
the most common method of assessing weakness (n=16, 59%), whilst slowness was measured using 
timed gait speed (n=19, 70%). Shrinkage was estimated by measuring weight loss over 12 months 
(n=15, 55%). 
There were eight studies (30%) that modified the Fried criteria for frailty and substituted the 
measurement of grip strength and gait speed for questionnaire based assessments of physical 
function. This method improves the feasibility of investigating frailty in large sample populations 
(59). However, Painter et al showed that using questionnaire based data over-estimated the reported 
prevalence of frailty in haemodialysis patients (19). 
Eleven studies (30%) employed a different measure to the Fried phenotype for frailty assessment. 
The most common of these, used in three studies, was the Clinical Frailty Scale. This is a clinical 
assessment of frailty developed from the Canadian Study of Health and Aging, which ranks fitness 
from a score of 1 (Very fit) to a score of 8 (severely frail and unlikely to recover from a minor 
illness) to a score of 9 (terminally ill) (22). Other scales used include the FI approach, which 
provides a quantitative assessment of frailty as the proportion of potential deficits in health (4). This 
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has been shown to be reproducible and be predictive of outcomes (60). Chao et al uses the FRAIL 
scale (Fatigue, Resistance, Ambulation, Illness, Loss of weight), which is related to the criteria 
developed by Fried et al but adds co-morbidity (illness) to self-reported assessment of the other 
criteria (61). Other measures used in the studies include the Groningen Frailty Indicator, 
Montesanto approach, Edmonton Frail Scale and a frailty check list (32, 37, 38, 49). 
 
Table 3 Systematic Review: Fried Frailty Assessment 
Original Definition of the Fried 
Phenotype by Fried et al (2) 
Interpretation of Fried Phenotype (n=27) 
Slowness 
Gait speed 
Gait speed (n=19, 70%) 
Questionnaire based assessment of physical function (n=7) 
Subjective perception of gait speed (n=1) 
Weakness 
Grip Strength 
Dyno metre measurement of grip strength (n=16, 59%) 
Questionnaire based assessment of physical function (n=6) 
Timed sit-to-stand (n=2) 
Self-report (n=2) 
Not state (n=1) 
Exhaustion 
Centre for epidemiological 
studies depression scale 
Patient self-report (n=13, 48%) 
Centre for Epidemiological Studies depression scale (n=6) 
Short form 36 Questionnaire (n=7) 
Short form 12 Questionnaire (n=1) 
Shrinkage 
>10 pounds of unintentional 
weight loss in 12 months 
Weight loss of 10 pounds over 12 months (n=15, 55%) 
Other measures of weight loss (BMI, 5% loss in total weight, 
lean appendicular mass, cachexia) (n=10, 40%) 
Not measured (n=2) 
Low Physical Activity 
Estimated kilocalories per week 
Patient self-report (n=11, 41%) 
Estimation of kilocalories (n=9, 33%) 
Questionnaire based physical activities scale (n=7) 
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Prevalence of Frailty 
Frailty was prevalent in patients with CKD, particularly in those on dialysis. Amongst the pre-
dialysis population the prevalence of frailty ranged from 7%, in a study of community dwellers with 
CKD (median estimated glomerular filtration rate (eGFR) = 49mLs/min), to 42.6% in a smaller 
study of patients with more severe CKD (mean eGFR = 27mLs/min) (16, 31). A study by 
Rodriguez et al had no patients who were frail, despite the sample population having severe CKD 
(mean eGFR =16) (35). However, patients in this study were referred into the clinic for 
consideration for dialysis; as a consequence of this screening process, only those who were ‘fit’ 
were selected (35). 
Frailty was more prevalent amongst patients on haemodialysis with the range being from 14% to 
73% (17, 47). There was no statistical comparison performed of the prevalence between dialysis 
and pre-dialysis patients because of the differences in the methods used to assess frailty. 
 
Glomerular Filtration Rate and Frailty 
Seven studies demonstrated a negative correlation between eGFR and the risk of frailty in pre-
dialysis patients with CKD (16, 27-30, 40, 42). Four of the seven studies used cystatin C to estimate 
eGFR, two used creatinine and one use iodine 145-iothalamate clearance. A study by Roshanravan 
et al found that the relationship between frailty and CKD was attenuated when using creatinine 
instead of Cystatin C to estimate GFR (28). This was supported by a more recent retrospective 
analysis by Ballew et al of 4987 community dwellers comparing cystatin C and creatinine clearance 
and the relationship with frailty (42).  In five studies, there was significant increase in the risk of 
frailty with eGFR less than 45mLs per minute (16, 27-30). In the remaining study, only patients 
with an eGFR less than 30mLs per minute were at a statistically significant increased risk of frailty 
because those with an eGFR >45 was used as the reference population (40). The study by Ballew et 
al demonstrated a significant relationship between odds of frailty with kidney function estimated 
with cystatin C, with the more severe the kidney disease the greater the odds of frailty (42).  
A study by Dalrymple et al in the Cardiovascular Health Study cohort showed that CKD was 
associated with an increased risk of incident frailty (27). Patients with CKD who did not have 
baseline frailty were followed for four years. The risk of developing frailty was inversely related to 
baseline eGFR (27). Patients with a eGFR between 15 and 45 mls/min were twice as likely to 
develop frailty over four years when compared with patients with normal eGFR (27). 
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Mortality, Hospitalization and Falls 
Eleven studies assessed adverse health outcomes in frail patients with CKD: seven in dialysis 
populations and four in pre-dialysis cohorts. Johansen et al examined frailty in dialysis patients and 
found an increased risk of death associated with frailty after one year of follow-up (Hazard Ratio 
[HR] 2.24, 95% CI 1.6 – 3.15) (46). Similarly, Bao et al and McAdams De-Marco et al reported a 
significant risk of mortality associated with frailty amongst the dialysis population (17, 44). The 
relationship between frailty and risk of death persisted after multivariate adjustment for age, sex and 
co-morbidities in all three studies. Alfaadhel et al demonstrated that each one point increase in the 
Clinical Frailty Scale was associated with an increased risk of mortality in haemodialysis patients 
(HR 1.22 [95% CI 1.04-1.13]; median follow-up: 1.7 years) (52). Bao et al and McAdams De-
Marco et al also demonstrated that frailty correlated with an increased risk of hospitalization in 
dialysis patients (17, 44).  
An analysis of a composite end-point of death or hospitalization reached statistical significance in 
the study by Johansen et al (HR 1.56 95% CI 1.36-1.79) (46). 
Roshanravan et al conducted a study in patients with CKD stages 1-4 and demonstrated that frailty 
was an independent risk factor for death or progression to dialysis (HR: 2.5 [95% CI 1.4-4.4]; 
median follow-up: 2.6 years) (28). In a study by Wilhelm-Leen et al, frailty increased the risk of 
death in patients with CKD and the risk was only partly attenuated in a multivariate model that 
adjusted for co-morbidities, inflammation and sarcopenia (HR 2.0 [95% CI 1.5 – 2.7]) (29). Studies 
by Delgado et al and Pugh et al also demonstrated an increased risk of mortality in patients with 
pre-dialysis CKD who were frail (41, 62). 
Frailty is a risk factor for falls in patients with end stage kidney disease. In a cohort of 
haemodialysis patients, McAdams De-Marco et al demonstrated that frailty increased the risk of 
falls by three times compared to those who were not frail (Relative risk [RR]=3.09, 95% CI 1.38 – 
6.90) (48). 
 
Frailty and the Kidney Transplant Recipient 
Three studies have investigated frailty in kidney transplant recipients. McAdams De-Marco et al 
demonstrated that incident frailty increased the risk of hospital readmission amongst kidney 
transplant recipients (RR= 1.61, 95% CI 1.18-2.19) (23). This risk persisted after adjustment for 
age, gender, co-morbidity, time spent on dialysis and donor factors. Another study by Garonzik-
Wang et al showed that frailty was an independent risk factor for delayed graft function (RR=1.94, 
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95% CI 1.13-3.36) (33). A second study by McAdams De-Marco investigated the change in frailty 
status after kidney transplantation (34). It found that the prevalence of frailty in the cohort 
decreased at 3 months of follow up and that patients who were frail before transplantation were 
twice as likely to have improvement in frailty score after transplantation (HR: 2.55 [95% CI: 1.71-
3.82]) (34). 
 
 
2.4 Discussion 
In this systematic review of frailty in patients with CKD, the prevalence of frailty increased with 
poorer kidney function and was highest in patients receiving dialysis.  Frailty was a significant 
predictor of adverse health outcomes, particularly in those with severe CKD stages. However, we 
found differences in frailty assessment and estimation of GFR and this may have influenced the 
reported prevalence of frailty. 
The Fried phenotype provided the basis for frailty assessment in the majority of the studies in this 
review (n=27, 73%). This is a well validated method of frailty assessment that classifies patients as 
frail, pre-frail or not frail categories (2). However, the Fried phenotype is less useful in grading the 
severity of frailty in populations where the prevalence of frailty is high (13). This is particularly 
problematic in patients on dialysis with one study demonstrating the prevalence of frailty be as high 
as 73% (17). Other methods, such as the FI, provide a continuous variable that may improve the 
discrimination of those patients at high risk, especially in patients on dialysis (39). 
The feasibility of using performance based tests of grip strength and slowness has proven to be 
problematic in retrospective studies that have used the Fried phenotype. One approach, proposed by 
Woods et al, involves replacing performance based tests with questionnaire based data to grade loss 
of physical function (59).  However, the correlation between measuring grip strength and slowness 
versus estimating physical function using the SF-36 questionnaire is poor (r=-0.34 for gait speed; 
r=0.14 for grip strength) (59). There were eight studies that modified the Fried phenotype and used 
the approach of using questionnaire data to replace the measured variables (17, 19, 31, 36, 39, 45, 
46, 58). Subsequently, Painter et al conducted a comparison of measuring gait speed and grip 
strength versus questionnaire data in quantifying the prevalence of frailty in haemodialysis patients 
(19). The study found the prevalence of frailty was 24% in the performance based group and 78% in 
the group using questionnaire data (19). Thus, the method by which the characteristics of the Fried 
phenotype of frailty are defined can considerably influence the prevalence of frailty in the 
population being investigated. 
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GFR estimation was different amongst the studies and this may influence the relationship between 
frailty and severity of CKD. The most common method of deriving an eGFR is by creatinine 
clearance, as reported in 14 studies. However, since this relies on muscle mass, the eGFR of frail 
patients who have lost muscle mass may be over-estimated. Another method of estimating GFR is 
by using cystatin C which is not influenced by muscle mass and this was utilised in three studies. 
The strength of the association between frailty and eGFR appears to be increased by using cystatin 
C. 
Regardless of the method of estimation, GFR seems to be an important mediator in the risk of 
frailty in patients with CKD. Six studies demonstrated that eGFR less than 45mLs/min was 
associated with increased odds of frailty (16, 27-30, 40, 42). There were differences in the 
calculation of the odds ratios because of different definitions of the eGFR of the reference 
population. This influenced the value of the odds ratios and prevented comparisons between studies. 
The prevalence of frailty ranged from 7% to 42.6% in pre-dialysis patients (16, 31). Amongst 
dialysis patients, the highest prevalence of frailty in the studies analysed was 73% (17). However, 
there was a wide range of frailty prevalence in the various CKD populations included in this review. 
Differences in the demographics of the study population, average eGFR, gender, co-morbidities and 
ethnicity may explain this difference. Furthermore, as demonstrated previously, the method of 
frailty assessment can considerably influence the proportion of patients classified as being frail. 
Patients with CKD who were frail were at increased risk of mortality and hospitalization. The risk 
of mortality was significant in both dialysis and pre-dialysis patients with CKD (17, 28, 29, 40, 41, 
44, 46, 52, 56-58). Frailty also predicted an increased risk of falls in patients with CKD (48, 62). In 
the kidney transplant recipient, frailty was associated with an increased risk of early hospital 
readmission and delayed graft function (23, 33). Patients who were frail prior to transplantation 
were also more likely to have improvement in frailty after transplantation (34). A previous 
systematic review by Walker et al found similar associations between frailty and adverse health 
outcome in patients with non-dialysis CKD (18). The association of frailty with mortality risk is 
consistent with other studies in community dwellers with normal renal function (5, 59). 
The findings of this systematic review have multiple implications for clinical practice. Firstly, it 
highlights the prevalence of frailty particularly in those with Stage 5 CKD and those on dialysis. 
Identifying these patients is important because frailty is associated with poor health outcomes. 
Frailty is a useful marker of health status and can be used to monitor response to interventions; an 
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example of this can be seen in the study by McAdams de Marco and colleagues who explored how 
frailty status changed before and after kidney transplantation (34). 
Whilst several articles in this systematic review were primary prospective studies, there is little data 
commenting on the length of time to complete these frailty assessments or the resources needed. 
One study, investigating the FI, demonstrated that a frailty assessment is feasible in an outpatient 
CKD clinic and could be conducted in approximately 10 minutes using a questionnaire (39). 
However, there is a need to compare different frailty assessment methods to establish which is 
better suited in a clinical setting. With the exception of kidney transplantation, there is no evidence 
for interventions that can change a patient’s frailty status if they have CKD. Frailty manifests when 
there is a critical number of deficits across multiple systems including those that regulate 
inflammation (63). Thus, it is likely that multiple strategies will be needed in tackling this issue of 
frailty in patients with CKD. 
There are strengths and limitations inherent in this systematic review. It encompasses a diverse 
range of populations with CKD including patients on dialysis and kidney transplant recipients. The 
total sample size is large with 53 000 patients.  However, differences in the method of frailty 
assessment and estimation of GFR between the studies meant there was considerable heterogeneity 
between studies. For this reason, a meta-analysis and summation statistics could not be performed 
to take full advantage of the large sample size. A large proportion of studies (n=18, 49%) used a 
secondary analysis in an existing cohort of patients to examine the relationship between frailty and 
CKD. This raises issues of external validity and whether the studies sufficiently addressed selection 
bias when presenting the findings. Unpublished results and a single article not available in the 
English language were excluded from this systematic review. Publication bias is a possibility 
because of exclusion of these studies. 
 
 
2.5 Conclusion 
Based on the number of studies, consistency and quality of the findings, there is strong evidence 
that frailty is associated with CKD and that patients with more severe CKD are more likely to be 
frail. Frailty predicts poor outcomes in patients with CKD including an increased risk of mortality 
and hospitalization.  
 
However, there is a need to better understand causality and why frailty is associated with adverse 
health outcomes in patients with CKD. There were no comparisons between patients with CKD and 
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patients with other chronic diseases, to establish whether CKD patients were unique in their higher 
likelihood of developing frailty. CKD may represent the cumulative consequences of deficits in 
health, such as hypertension, diabetes or chronic glomerulonephritis that result in the phenotypic 
expression of frailty. The fact that worse kidney function increases the likelihood of frailty is 
suggestive that kidney disease itself correlates with frailty. It is difficult, however, to definitively 
establish the contribution of kidney disease to frailty versus the diseases that caused the kidney 
disease in the first place.  
 
Further research should also explore different methods of frailty assessment that better delineate 
those who are most frail and who may benefit from targeted intervention. A categorical description 
of frailty is useful in describing frailty in large populations. A continuous variable would accurately 
define the severity of frailty, particularly in patients with more severe CKD where the prevalence of 
frailty is high. Consistency in how frailty is defined is important in comparisons between cohorts of 
patients with CKD. 
 
Following is a prospective study of investigated the use of the frailty index in patients with dialysis 
and pre-dialysis CKD.  
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CHAPTER 3: PROSPECTIVE STUDY OF FRAILTY IN CHRONIC KIDNEY DISEASE3.1  
3.1 Introduction 
The systematic review highlighted potential avenues for further research into frailty in patients with 
CKD. Firstly, there is a need to explore other frailty assessment methods that better delineate risk, 
particularly amongst dialysis patients, where the prevalence of frailty may be high. The FI is one 
such method that provides a continuous variable to better define frailty in a population. Much of the 
research into frailty in patients with CKD is based on populations outside Australia and New 
Zealand. An FI-CKD pilot study provided evidence that an FI could be a feasible means of frailty 
quantification in patients with CKD (39). However, there is a need to expand this data set to 
patients on dialysis as well. Finally, we need a greater understanding of how interventions modify 
frailty over time. Examples specific to patients with CKD include the effects of dialysis or kidney 
transplantation. 
 
3.2 Methods 
Aims  
The aims of the FI-CKD study were: 
1. Assess the relationship between FI and kidney function.  
2. Examine the effects of dialysis on FI  
3. Investigate if baseline frailty is associated with increased risk of mortality and 
hospitalization. 
Hypotheses 
1. Patients with reduced kidney function would have a greater FI. 
2.  FI would greater in those on dialysis  
3. Baseline frailty would be associated with increased risk of adverse outcomes at 12 months 
follow-up 
 
Study Design and Settings 
The FI-CKD project was a prospective, multi-centre longitudinal study of the FI in patients with 
CKD. Recruitment began with a pilot study in August 2013 at the Princess Alexandra Hospital, 
Brisbane, Australia. The second phase of recruitment commenced on July 2014 and continued to 
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January 2015 and included patients recruited from Whangarei Dialysis Centre, North Island, New 
Zealand.  
The Princess Alexandra Hospital is a 780 bed tertiary hospital in the metropolitan centre of 
Brisbane Australia. It has one of the largest CKD services in Australia and includes outpatient 
haemodialysis centre, outpatient clinic and facilities to support patients on peritoneal dialysis and 
home haemodialysis. The Princess Alexandra Hospital is the centre for kidney transplantation in the 
state of Queensland.   
The Whangarei Dialysis Unit is the largest dialysis unit in the Northland of New Zealand. It caters 
for 58 patients on haemodialysis and works in association with Whangarei Hospital.  
There were four data collectors involved in interviewing patients at the two recruitment sites. The 
three data collectors at the Princess Alexandra Hospital include the principle study investigator 
(Rakin Chowdhury), Mr Mitchel Krosch (Medical Student) and Sebastian Senff (Medical Student). 
There was a fourth data collector in Whangarei Dialysis centre, Ari (Medical Student). 
 Internal validity was achieved by training of the data collectors and by consistency with frailty 
assessment form. Furthermore, the frailty assessment form counts the majority of deficits as 
dichotomous variables which minimizes subjectivity in the assessment.   
 
Statistical Power 
The target sample size for the study was 250 patients. Assuming adverse outcomes (mortality and 
hospitalization as a composite outcome over one year) occur in 25% of older people in the frailest 
quartile and 5% of older people in the fittest quartile, and setting alpha at 5% and power at 80%, the 
sample size estimate would 50 per quartile.  
Eligibility Criteria and Recruitment 
Outpatients in nephrology clinics and dialysis centres at the two centres for data collection were 
invited to participate in the study. Patients who agreed to participate were provided with written 
information about the project and consent was attained (Appendix 2). 
Participants were eligible for inclusion if they were older than 18 years of age and had CKD. 
However, participants were excluded if they were not able to speak the English language and no 
interpreter was available. 
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Measures 
Frailty measures utilized 
Frailty was measured using the FI-CKD (Frailty Index in CKD). The FI-CKD was previously 
developed in a pilot study and showed feasibility in the setting of outpatients with CKD (39). The 
FI-CKD involves using the frailty assessment form (Appendix 3), which includes 58 coded items 
which represent potential deficits in health. Deficits can be a symptom, sign, disease, disability or 
laboratory measure that corresponds with adverse health outcome (4). For a variable to be a deficit 
is must satisfy five criteria (64): 
• The variable must be associated with health status 
• The chosen variables should cover a range of health status. For instance, the FI-CKD covers 
deficits in perceived health status co-morbidity, cognition, polypharmacy, mental well-
being, sleep, activities of daily living, mobility and communication.  
• The prevalence of the deficit should increase with age 
• The deficit should not completely saturate with age. An example of a variable that does 
saturate with age is presbyopia (so presbyopia cannot be used as a deficit) 
• If the FI is re-applied to the same individual over time, then the same set of variables should 
be used 
 
The deficits were ascertained predominantly by patient self-report. Sometimes patients with 
complex histories do not have a complete recollection of all their medical problems or their 
medications. Furthermore, cognitive impairment would impair the recall of some this information. 
For this reason, deficits surrounding co-morbidity and medications were cross checked with the 
patient’s electronic medical record to ensure accuracy. The FI-CKD was calculated as number of 
deficits in health divided by the total number of deficits measured as per previous methodology (4, 
64). 
There were other frailty assessment tools that were considered for the prospective study. One 
method involves using interRAI (Resident Assessment Instrument) which is a comprehensive 
assessment of patients’ physical, cognitive and psycho-social functioning (65). The data is derived 
from a variety of different sources including the patient, medical records, family and health care 
providers involved in the patient’s treatment (65). A FI can be derived from the detailed information 
provided by interRAI and this has previously been demonstrated in an acute care setting (65). 
However, interRAI would not be feasible in an outpatient setting predominantly because of time 
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constraints. Patients were often opportunistically approached whilst waiting for an outpatient clinic 
appointment and so the time with the patient would be 20 minutes at most. Furthermore, much of 
the information provided by interRAI requires care giver assessment (65). Most patients presenting 
to the outpatient clinic came alone and so again this was not deemed as feasible for the study.  
Other approaches to frailty assessment such as the Fried phenotype were considered. As mentioned 
in the systematic review, the disadvantage of using the Fried phenotype include the feasibility of the 
performance based test and the categorical classification of frailty in the population. This may be 
less useful in populations where the prevalence of frailty is high, such as patients with CKD. The 
other tools available such as the Clinical Frail Scale, FRAIL scale and Montesanto tool all provide a 
categorical classification of frailty and have similar limitations. 
 
Estimation of kidney function 
GFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation and serum 
creatinine (66). Estimated GFR with this approach was used because of its ease of availability and 
its widespread use in clinical practice in the study settings. Alternative measures include Cystatin C, 
which has advantages particularly in the assessment of kidney function in patients who are frail. 
Serum creatinine is produced by muscle breakdown and theoretically a frail patient with reduced 
muscle mass would have a lower production of creatinine thus resulting in overestimation of kidney 
function (28). Cystatin C is not dependent on muscle mass and previous studies have shown a 
stronger negative correlation between GFR estimated with cystatin C and frailty when compared 
with serum creatinine and frailty (28). However, Cystatin C is not widely utilized in clinical 
practice in Australia or New Zealand and it was not routinely available at the time of data 
collection.  
GFR was also stratified into CKD stage according to the K/DOQI guidelines (National Kidney 
Disease Outcome Quality Initiative) (67). The most recent blood test to the date of assessment and 
the date of follow up was chosen to estimate GFR.  
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Outcomes 
A review of health records was conducted at 12 months post study recruitment by the principal 
study investigator (RC). At this time, outcome data including mortality, hospitalization data and 
change in eGFR from baseline was attained from electronic medical records.  
  
Statistical Analysis 
Frailty indices for each participant were calculated as the sum of deficits divided by the total 
number of deficits measured (58 items). Information about patient demographics and co-morbidities 
were presented as frequencies and compared between dialysis and pre-dialysis patients using t-test 
for continuous variables with normal distributions and non-parametric tests for those not normally 
distributed. The Chi-squared test was used in comparisons of categorical data. 
In the analysis of kidney function and FI, patients on dialysis were excluded because dialysis itself 
would be a confounding variable. Univariate association between FI and eGFR was tested using 
Pearson correlation coefficient. Further analyses were conducted between FI and CKD stage using 
ordinal regression analysis with adjustments for age and gender. 
The outcomes of mortality and hospitalization were treated as dichotomous variables and analysed 
with logistic regression with adjustments for age, gender and dialysis status. The FI was multiplied 
by 10 to provide more meaningful reporting of risk when calculating odds ratios (68). Results were 
expressed as the odds of the outcome occurring per unit (0.1) increase in frailty and this follows a 
similar outcome analysis using the FI in a previous study (68). 
Statistical analysis of data was conducted with IBM SPSS (Version 23.0). 
 
Ethics 
The FI-CKD study was approved by the respective Ethics Boards at the Princess Alexandra 
Hospital, Brisbane, and Whangarei Dialysis Centre, New Zealand. A copy of the ethics approval at 
the Princess Alexandra Hospital is provided in Appendix 4. Participants were given written 
information and signed informed consent forms were completed (see Appendix 3). Patients were 
de-identified at the time of analysis.  All data was kept in a secure location and databases password 
protected. 
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3.3 Results 
 
Demographics 
There were 314 participants recruited into the FI-CKD study and 42% (n=132) were female.  
The majority of the sample were pre-dialysis patients (n=228, 73%). Of those on dialysis (n=86, 
27%), the most common type of dialysis was haemodialysis (n= 76, 88%) (Figure 2). Average age 
across the cohort was 64 years (SD 13.4 years) and the mean number of co-morbidities was 7 (SD 
3). The most common aetiology causing CKD in the cohort was diabetic nephropathy (n= 102, 
n=32.5%), followed by renovascular nephrosclerosis (n=35, 11.1%), hypertensive nephrosclerosis 
(n=19, 6.1%) and focal segmental glomerulosclerosis (n=19, 6.1%) (Table 4). 
Mean FI was 0.29 (SD 0.13), which corresponds to the Clinical Frailty Scale category of mild (FI 
0.22) to moderate (FI 0.36) (22). 
 
  
 
Figure 2 FI-CKD study: Demographics 
 
 
 
 
228, 73%
76, 24%
10, 3%
Sample Characteristics
Pre-dialysis CKD Haemodialysis Peritoneal Dialysis
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Table 4 FI-CKD study: Aetiology of CKD in the cohort 
 
Aetiology Number (%) 
Diabetic nephropathy 102 (32.5) 
Renovascular nephrosclerosis 35 (11.1) 
Hypertensive nephrosclerosis 19 (6.1) 
Focal segmental glomerulosclerosis 19 (6.1) 
Autosomal dominant polycystic kidney disease 17 (5.4) 
Unknown aetiology 17 (5.4) 
Other aetiologies 17 (5.4) 
IgA Nephropathy 9 (2.9) 
Obstructive Uropathy 9 (2.9) 
Lupus nephritis 8 (2.5) 
Mesangioproliferative glomerulonephritis 7 (2.2) 
Reflux nephropathy 7 (2.2) 
Analgesic nephropathy 6 (1.9) 
Presumed chronic glomerulonephritis 6 (1.9) 
Other aetiologies 53 (17) 
 
 
 
Dialysis and Pre-dialysis Patients 
There was no significant difference in mean frailty between patients on dialysis with those pre-
dialysis (p=0.519). The two cohorts had similar demographics with no significant differences in 
age, gender or number of co-morbidities or aetiology of CKD (Table 4). 
Table 5 FI-CKD study: Comparison of the cohort between dialysis and pre-dialysis patients 
 
 Pre-dialysis Dialysis 
Number 228 86 
Age (Standard deviation) 62.9 years (SD 11.7) 64.6 years (SD 14.0) 
Gender (% female) 36 (41.9) 96 (42.1) 
Number of Co-morbidities (IQR) 6 (4-8) 7 (5-9) 
Frailty Index (IQR) 0.25 (0.1843 – 0.3491) 0.27 (0.1940 – 0.3750) 
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Frailty Index and Kidney Function 
FI amongst pre-dialysis patients was correlated to eGFR and CKD stage. The average eGFR 
amongst the pre-dialysis cohort was 34 mL/min/1.73m2 which corresponds to CKD stage 3b. 
The relationship between FI and eGFR was investigated using linear regression. There was inverse 
correlation between eGFR and FI (Pearson correlation: -0.3, p<0.01). However, this relationship 
was not significant when adjusted for age and gender. 
Kidney function was also stratified into CKD stage. Analysis using ANOVA with Bonferroni post 
hoc tests, demonstrated that patients with CKD stage 5 were frailer compared to those with CKD 
stage 1, 3A or 3B (Table 6). 
The relationship between FI and CKD stage remained significant after adjustment for age and using 
ordinal regression analysis (p<0.05). 
 
Table 6 FI-CKD study: CKD stage and FI 
 
 
CKD Stage p value 
1 
n= 17 
(7.6%) 
2 
n=12 
(5.3%) 
3A 
n=28 
(12.4%) 
3B 
n=50 
(22.2%) 
4 
n=76 
(33.8%) 
5 
n=42 
(18.7%) 
 
Age mean 
(SD) 
44  
(37-52) 
48  
(39-58) 
63  
(58-68) 
66  
(62-69) 
70  
(67-72) 
69 
 (66-73) 
P<0.05 (vs CKD 
Stage 1 and 2) 
FI median 
(IQR) 
 
0.17 
(0.16-
0.28) 
0.22 
(0.16-
0.42) 
0.23 
(0.15-
0.25) 
0.23 
(0.21-
0.27) 
0.31 
(0.29-
0.37) 
0.31 
(0.27-
0.44) 
 
 
 
FI was also compared to change in kidney function from baseline after 12 months of follow up. 
There was no significant correlation between FI at baseline to change in eGFR over 12 months 
(Spearman’s correlation coefficient = -0.04; p = 0.56).  
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Frailty Index and Mortality 
The relationship between FI and mortality at 12 months follow up was investigated with binary 
logistic regression. The statistical model included age, FI, gender and dialysis status to investigate 
which factors were associated with an increased risk of mortality. Higher FI correlated with an 
increased risk of mortality (p=0.001). For each 0.1 unit increase in FI, there was a 1.8 fold increased 
risk of death (OR: 1.8; 95% CI 1.77 – 2.44). The relationship between FI and mortality remained 
independent when adjusted for other variables. 
Age and being on dialysis were also associated with an increased risk of mortality; gender was not 
significantly associated with mortality in this analysis. 
 
Frailty Index and Hospitalization 
FI was compared with the risk of hospitalization in 12 months of follow up after study recruitment. 
In binary logistic regression, FI correlated with an increased risk of hospitalization (OR 1.3 95% CI 
1.06-1.5). In the statistical model, age and being on dialysis were also associated with an increased 
risk of hospitalization. 
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3.4 Discussion 
 
There was a significant burden of frailty in this prospective study of 314 patients with CKD. The 
average FI was 0.29 (SD 0.13), representing a clinical description of mild to moderate frailty. 
Patients with poorer kidney function and a higher stage of CKD had significantly greater FI. 
Furthermore, FI was associated with an increased risk of mortality and hospitalization in patients 
with CKD; this risk was independent of age and gender.   
FI inversely correlated with kidney function; the lower the eGFR the higher the FI. However, the 
relationship between FI and eGFR did not fit a linear or logarithmic model (Pearson correlation: 
0.303, p<0.01). The relationship between kidney function and CKD stage was significant on ordinal 
regression analysis after adjusting for age and gender.  
There are limitations in correlating frailty with kidney function estimated with serum creatinine. 
Creatinine is a product of muscle breakdown and is both secreted and filtered in the nephron (69). 
Frail patients may have reduced muscle mass resulting in less creatinine produced and over 
estimation of GFR (30). Previous studies have used cystatin C to estimate GFR, which improves the 
correlation with frailty because it is not dependent on muscle mass (27, 28, 30). The relationship 
between frailty and kidney function may not be simple. Further research is needed to identify 
predictors of frailty in patients with CKD and why some patients with poor kidney function may not 
be frail. 
FI was compared between patients on dialysis and those pre-dialysis from all CKD stages. There 
was no significant difference in FI between the two cohorts. In this study, patients on dialysis had 
similar characteristics to those pre-dialysis in terms of age, gender and number of co-morbidities. 
The results of this study contrast with the systematic review of frailty in CKD, which found studies 
investigating patients on dialysis had a higher prevalence of frailty.  However, this is the first study 
to compare pre-dialysis and dialysis patients in the same prospective methodology with the same 
method of frailty assessment and in the same study setting. As acknowledged in the systematic 
review, it is difficult to compare the prevalence of frailty between studies because of the differences 
in how frailty is assessed in the dialysis and pre-dialysis populations.   
We hypothesised several factors that may explain the similarity in frailty in dialysis and pre-dialysis 
patients in the FI-CKD study. Firstly, patients with stage 5 CKD who are frail and not fit for 
dialysis would be selected out of the dialysis cohort. Hence, selection bias would confound the 
relationship between frailty and dialysis status. The FI-CKD study had a limited proportion of 
patients in the dialysis cohort (n=86, 27%), which would limit the statistical power in the cohort 
46 
 
analysis. Using the FI would impact on direct comparisons to previous literature which commonly 
used the Fried frailty classification. However, there was good internal validity in that the same 
method of frailty assessment was used to assess frailty in the dialysis and pre-dialysis cohorts. Thus, 
the method of assessment should not impact on the ability to find a difference between the cohorts.   
FI was independently associated with increased risk of mortality and hospitalization. For each 0.1 
unit increase in the frailty index, the risk of mortality increased by 1.8 (95% CI 1.8 – 2.4). Other 
risk factors for morality in this population were age and being on dialysis. This is consistent with 
previous literature, which finds frailty is associated with mortality in both pre-dialysis and dialysis 
patients with CKD (17, 28, 29, 40, 44, 46, 52). The association between FI and mortality was also 
comparable to previous literature in study populations other than CKD. One study, investigating 
adverse health outcomes in a tertiary rehabilitation facility found that for each 0.1 unit increase in 
the frailty index, the hazard ratio for mortality increased by 1.63 (95% CI 1.29-2.06) (68). The risk 
of hospitalization also correlated significantly with FI (OR 1.3 95% CI 1.06-1.5). In the statistical 
model, age and dialysis status were also associated with an increased risk of hospitalization.  
Frailty has been associated with number of other co-morbidities. It is important to explore these 
associations because CKD is often a secondary manifestation especially diabetes and hypertension. 
Furthermore, a recent retrospective study in community dwellers with CKD showed that presence 
of hypertension or diabetes increased the risk of frailty in patients with an eGFR<30mLs/min (43).  
 
 
Frailty and Hypertension 
The relationship between frailty and hypertension is complex. Management of hypertension reduces 
the risk of disease progression in patients with CKD. However, a meta-analysis reviewing the 
treatment of hypertension in patients above 80 years of age showed a 14% increased risk of 
mortality in trials that were double-blinded (70). However, subsequent analysis of the HYVET 
(Hypertension in the Very Elderly) randomised controlled trial, which investigated BP control using 
an angiotensin converting enzyme inhibitor (ACEI) and thiazide diuretic combination, showed no 
relationship between frailty (measured with FI) and adverse health outcomes in patients above 80 
years of age (71). Indeed, it was shown that mortality benefits and benefits in terms of stroke 
prevention and cardiovascular disease were retained even in those who were frail.  It should be 
noted that patients in the HYVET study had less stringent BP targets (150/80 mmHg) compared 
with current guidelines for patients with proteinuria for instance (71). This indicates that blood 
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pressure control, at least with an ACEI or in combination with a thiazide, should not be denied to 
patients who are frail. Furthermore, further research is needed in those patients at risk of falls and 
those with dementia.  The mean FI in the HYVET study was 0.19 indicating a fitter group of 
patients at least when compared to the FI-CKD study.  
 
Frailty and Diabetes Mellitus 
An interesting relationship exists between diabetes, frailty and sarcopenia. Diabetes in known to 
accelerate muscle loss which may be exacerbated by the presence of frailty (72). Insulin resistance 
results in an overall catabolic state within skeletal muscle resulting in muscle loss (72). Diabetes 
also promotes the pro-inflammatory milieu, and this again provides a link between diabetes and 
frailty (72). A prospective study in 1750 patients has shown an increased odds ratio of developing 
frailty (OR 2.18 95% CI 1.42 – 3.37) if the patient had diabetes at baseline (73). In patients with 
end-stage kidney disease, diabetes is associated with increased mortality risk. A multicentre cross-
sectional study in one million participants with CKD showed that diabetes was associated with an 
increased risk of all-cause mortality and cardiovascular mortality (74). It is not known whether 
management of diabetes impacts on frailty in patients with CKD and this is certainly an avenue for 
future research.  
Strengths of the FI-CKD study 
The FI-CKD study has several strengths. It uses a repeatable, validated method of frailty assessment 
(frailty index), to investigate the spectrum of frailty in patients CKD. The FI has advantages over a 
classification system, in that it better delineates risk particularly in populations where the incidence 
of frailty is high. The FI also does not rely on performance-based data such as gait speed or hand 
strength, and this allows for easier adoption into clinical practice and to large populations.  This is 
also one of the first studies that compares the prevalence of frailty between dialysis and pre-dialysis 
patients with the same method of frailty assessment. Furthermore, it provides more data about the 
spectrum of frailty in outpatients with CKD in Australia and New Zealand.  
 
Limitations of the FI-CKD Study 
There were limitations to the FI-CKD study. The number of patients in the dialysis cohort was 
small in proportion to the overall sample population and this reduced the statistical power in the 
cohort analysis. As acknowledged previously, measuring kidney function using serum creatinine in 
patients who are frail may over estimate kidney function because of reduced muscle mass. The 
average age of patients in this study was 64 years (SD 13.4 years) and so the FI in this population 
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would be different compared to older patients with CKD. FI was not directly compared with the 
Fried approach to classification of frailty. The previous pilot study did demonstrate that FI 
correlated with a modified Fried phenotype (p<0.001) (39). The goals of the FI-CKD study were to 
investigate how FI changes with severity of kidney function and dialysis status and not to prove its 
diagnostic superiority over the Fried phenotype. It is thought that both models provide alternative 
and valid answers to the question of how best it is to measure frailty in patients with CKD.  
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CHAPTER 4: CONCLUSION 
This thesis demonstrates that patients with CKD have a significant burden of frailty. The systematic 
review showed that frailty is highly prevalent in both dialysis and pre-dialysis patients with CKD 
and that frailty increases with increasing severity of kidney function. However, there was marked 
heterogeneity in the definition of the Fried criteria in the studies assessed in the systematic review. 
This was performed to assist feasibility in assessing frailty in large cohorts of patients or in 
retrospective studies.  
The prospective study included in this thesis utilized a more precise assessment of frailty by using 
the FI. It again demonstrated that outpatients with CKD have a significant burden of frailty that 
changes with kidney function. The overall FI-CKD of the sample population was 0.29 
corresponding to a clinical description of mild to moderate frailty. Kidney function measured by 
CKD stage correlated significantly with FI. However, the correlation between FI and eGFR was 
attenuated by the limitations of using serum creatinine to estimate GFR in a frail population. 
Interestingly, there was no significant difference in FI between pre-dialysis and dialysis patients. 
This perhaps reflects selection bias, in that patients on dialysis represent a fitter selection of patients 
with stage 5 CKD. FI correlated significantly with mortality and hospitalization and will prove to be 
a useful tool in delineating risk amongst patients with CKD.  
 
4.1 Implications for policy and practice 
The FI does not require performance based data, which lends itself to be integrated into electronic 
medical records. One recent study has validated an electronic FI which utilizes 30 deficits that have 
been derived from medical records in a population of 900,000 patients in the UK (75). This showed 
good internal validity and identified patients at risk of mortality, hospital admissions and nursing 
home admissions (75). A similar system could theoretically be employed in outpatient clinics of 
patients with CKD and could support decision making in real time, identify at risk individuals and 
direct community services to benefit these patients.  
The effect of dialysis in older patients with stage 5 kidney disease and its impact on frailty is a 
subject of future research. Although several studies have shown that patients on dialysis are frail, 
the time course of this relationship between frailty and dialysis initiation needs to be better defined. 
One study has shown that earlier initiation of dialysis was associated with increased frailty and an 
increased risk of mortality (17). However, once this analysis was adjusted for frailty, the 
relationship between the early dialysis initiation and mortality became non-significant (17). A study 
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by Alfaadel et al further highlighted that frailty at dialysis initiation was independently associated 
with an increased risk of mortality (52). This indicates that the patient’s frailty is the more 
important predicator of poor outcome from dialysis rather than the time when dialysis is initiated. 
Dialysis is a powerful modality which treats fluid overload and toxin accumulation and patients do 
experience a symptomatic benefit after dialysis intervention. Older patients who are fit should not 
be denied the opportunity to experience these benefits with dialysis initiation. The FI may provide 
useful information before dialysis initiation to identify those patients who are frail and may be 
better be served by a conservative approach to their CKD management. Indeed, the challenges of 
initiating frailty in older patients with stage 5 CKD is the topic of a current research project by my 
colleagues at UQ. The aim of their study is to investigate the impact of dialysis or conservative 
management on frailty status and perceived quality of life.  
More recent research is emerging on the impact of interventions other than dialysis on frailty status 
in patients with CKD. One study in Korea, has investigated the impact of exercise in patients with 
end stage kidney disease. Patients who were more active had significantly lower rates of frailty, 
reduced risk of falls and improved perceived health related quality of life (76).  
FI has been applied outside patients with CKD and provides a way of predicting those vulnerable 
older patients who are more likely to have a detrimental impact to their level function after an 
insult. For instance, one study utilized the FI as part of a comprehensive geriatric assessment in 
patients presenting to hospital after hip fracture (77). In this setting, FI independently predicted 
adverse health outcomes in 178 patients with a mean FI of 0.34 (77). Patients who were classified 
as having high frailty (FI>0.4) were significantly longer length of stay in hospital compared to those 
with low frailty (FI<0.25). This is significant in the provision of services and identifying those 
patients who may need extensive rehabilitation if there are ever to return home at a reasonable level 
of function.  
Although the topic of this thesis has been frailty, recent research has focused on identifying 
resilience factors in the elderly and the positive impact this has on survival. The American 
Psychological society defines resilience as: the process of adapting well in the face of adversity, 
trauma, tragedy, threats, or significant sources of stress,” or “bouncing back” from difficult 
experiences. A recent systematic review of studies investigating resilience has found the following 
mental, physical and social factors that are associated with resilience (78): 
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Table 7 Conclusion: Resilience Factors 
Mental Social Physical 
Adaptive coping styles Community involvement ADL independence 
Gratitude 
Contact with family and 
friends 
High mobility 
Happiness Self-rated successful aging Physical health 
Lack of cognitive failures Sense of purpose Self-rated successful aging 
Mental health 
Social support and 
connectedness 
 
Optimism/hopefulness Social support seeking  
Positive emotions/regulation Strong, positive relationships  
 
The presence of resilience is associated with positive health outcomes including longevity, better 
quality of life and mental well-being (78). Resilience research highlights the importance of 
recognising a patient’s assets in conjunction with frailty when considering their predicted response 
to an intervention such as starting dialysis.  
 
4.2 Future Research 
The FI-CKD study forms part of a programme of research that investigates the efficacy of the FI in 
identifying patients at risk of adverse health outcomes in patients with CKD. Future research will be 
directed into applying the FI to clinical practice as a potential decision-making tool. An example of 
this is the research being undertaken by Chen and colleagues which is examining the effects of 
dialysis initiation versus conservative management on frailty in older patients with CKD.   
This study utilized the FI in a cross sectional prospective study. More longitudinal data is needed to 
establish the effects of dialysis initiation on frailty over time and the impacts this has on outcomes.  
This leads to the question about what can be done to reverse the effects of frailty in patients with 
end stage kidney disease. Interventions that merit investigation include the impact of exercise. This 
may be a potential avenue to reverse the process of sarcopenia and frailty.  The role of hypertension 
and diabetes on the development of frailty needs to be explored in greater detail. Frailty is 
associated with changes in body composition especially in patients on dialysis (79). Could changes 
in diet and changes to BMI have an impact on frailty in individuals with Stage 5 CKD?  
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4.3 Personal Reflection 
I have been fortunate to be part of the renal unit at the Princess Alexandra Hospital as a medical 
student, an intern and registrar. I am in debt to the many patients who have volunteered their time to 
teach me about their experiences with living with CKD from the pre-dialysis stage to starting 
dialysis and receiving their first kidney transplant. I have witnessed the impact dialysis can have in 
reversing some of the effects of CKD, its limitations and the changes it has on the patient over time.  
My research has taught to me to look a little harder at the patient and think about their trajectory in 
healthcare. Sometimes, I like to look back at their presentations and identify potential opportunities 
where things could have been done differently to the benefit of the patient. I believe thinking about 
frailty is an important part of clinical practice and being more scientific and accurate in frailty 
assessment is crucial in improving my role as a medical registrar.  
I have attained several new skills in completing this thesis and my MPhil. These include 
formulating a research question, preparing a study protocol, submitting an ethics application, data 
collection, managing a research team and a team of data collectors, completing a systematic review, 
publishing a paper to a peer reviewed journal and oral presentations at unit meetings and 
conferences.  
I hope my research will be beneficial to the care of patients with CKD in the future and contribute 
to our understanding of frailty in general.  
 
4.4 Publications Arising from the Thesis 
A systematic review investigating frailty in CKD was conducted as part of literature review. This 
has been published in the Archives of Gerontology and Geriatrics 2017 (24). An abstract of the 
preliminary results has been presented to the Australia/New Zealand Geriatric Medicine Conference 
2016. The results of the FI-CKD will be submitted for publishing in a peer reviewed journal (see 
Appendix 5 for a proposed abstract for the prospective study). 
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Appendix 1: Frailty and Chronic Kidney Disease: A systematic review 
 
Abstract 
Objective: Frailty is associated with increased vulnerability to poor health. There is growing interest 
in understanding the association between frailty and chronic kidney disease (CKD). This systematic 
review explored how frailty is measured in patients with CKD and the association between frailty 
and adverse outcomes across different stages of renal impairment.  
Study design:  Systematic analysis of peer reviewed articles.  
Data Sources: Pubmed, Medline, Web of Science and Cochrane were used to identify the articles.  
Data synthesis: Articles published before the 17th of September 2016, that measured frailty in 
patients with CKD were eligible for the systematic review. Two independent researchers assessed 
the eligibility of the articles. Quality of the articles was assessed using the Epidemiological 
Appraisal Instrument.   
Results: The literature search yielded 540 articles, of which 32 met the study criteria and were 
included in the review (n=36 076, age range: 50 – 83 years). Twenty-three (72%) studies used or 
adapted the Fried phenotype to measure frailty. The prevalence of frailty ranged from 7% in 
community-dwellers (CKD Stages 1 – 4) to 73% in a cohort of patients on haemodialysis. The 
incidence of frailty increased with reduced glomerular filtration rate. Frailty was associated with an 
increased risk of mortality and hospitalization.  
Conclusion: Frailty is prevalent in patients with CKD and it is associated with an increased risk of 
adverse health outcomes. There are differences in the methods used to assess frailty and this hinders 
comparisons between studies.       
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Introduction  
Frailty describes a state of increased vulnerability to health problems. There are two acknowledged 
conceptualisations of the term, which have resulted in different approaches to its measurement.1 
Firstly, frailty can be thought of as a syndrome with sarcopenia as the key pathophysiological 
feature2: this facilitates the measurement of frailty using a specific set of signs and symptoms. This 
approach, developed by Linda Fried, defines five criteria that establish a phenotype for frailty: 
slowness, weakness, low physical activity, exhaustion and shrinkage.2  
The second approach, known as the frailty index approach, views frailty as a state of deficit 
accumulation that begins at the cellular level and leads to a loss of redundancy in organ systems3-5; 
here, frailty is quantified by counting deficits across multiple systems.  
Patients who are frail, regardless of how it is measured, experience a decline in physical function 
and are at an increased risk of adverse health outcomes. Although there is a strong positive 
correlation between frailty and chronological age, patients with chronic disease also appear to be 
predisposed to frailty.6  
The relationship between chronic kidney disease (CKD) and frailty is not completely understood.  
Studies have shown that inflammation is associated with frailty in many chronic diseases and this 
suggests a ‘shared pathophysiology’ of frailty.3 In particular, pro-inflammatory cytokines 
interleukin-6 and tumour necrosis factor alpha may have a role in age-related muscle atrophy and 
sarcopenia, which are key features of frailty.7 Shlipak et al8 demonstrated that there are raised levels 
of pro-inflammatory cytokines in CKD patients. However, further research is needed to investigate 
the causal relationship between inflammation and frailty specifically in patients with CKD.  
A previous systematic review (studies published to 2012) explored frailty in pre-dialysis patients 
and showed an association between frailty and CKD.9 Here, we update and expand this evidence, by 
including patients on dialysis as well as in kidney transplant recipients. The aims of the systematic 
review were to explore how frailty is measured in patients with CKD, evaluate the relationship 
between frailty and severity of kidney failure and assess whether it predicts outcomes such as 
mortality and hospitalization.  
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Method 
 
Search strategy  
The following search terms were used to identify articles that assessed frailty in patients with CKD:  
‘Chronic kidney disease’ OR ‘kidney disease’ OR ‘Renal Insufficiency’ OR ‘dialysis’ OR ‘kidney 
failure’ OR ‘renal failure’ AND ‘frailty’. 
The focus of this review was on assessment of frailty status. Thus, we did not broaden the search 
criteria for frailty to include geriatric or functional assessments. The literature search was conducted 
using online databases including Pubmed, Medline, Web of science and Cochrane libraries. The 
reference lists of key papers were also examined for articles of relevance. 
 
Selection criteria 
Inclusion criteria for the systematic review were primary research articles that analysed the 
prevalence of, or relationship between, frailty and CKD.  All studies investigating frailty in dialysis, 
pre-dialysis and kidney transplant recipients published before 17th September 2016 were eligible for 
inclusion. Articles were excluded if they were not available in the English language. Where there 
were articles that involved different analyses on the same study population, the article that best 
answered the aims of the systematic review was selected for analysis.  
 
Data analysis 
Two independent reviewers examined the abstracts for relevance to the study criteria. Where there 
was a difference of opinion about inclusion of the study, a third reviewer was consulted. 
A data extraction table was created which included information about the demographics of the study 
population, the sample size, method of frailty assessment, CKD measurement and outcome 
variables such as mortality rates and hospitalization.  
Each article in the systematic review was assessed for quality using the Epidemiological Appraisal 
Instrument (EAI). The EAI, developed by Genaidy and colleagues, provides a systematic appraisal 
of study quality across the domains of sample selection, exposures and outcomes, statistical analysis 
and adjustment for co-variates and confounders.10 Each domain was scored out of 2, and the 
average across the domains was expressed as the overall EAI score. The closer the score to 2 the 
better the article.   
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Due to the significant heterogeneity in the sample populations, method of frailty assessment, and 
CKD measurement a meta-analysis was not performed.    
 
Results:  
The literature search yielded 540 articles. Forty-eight articles met the inclusion criteria and were 
selected for full text review. After the full text review a further 16 studies were excluded from 
further analysis for the following reasons: article did not measure frailty in the study population 
(n=3); not available in English (n=2); did not measure frailty in a CKD population (n=3); repeated 
analyses on the same study population (n=8); and one article whose results were not available for 
the systematic review.   This resulted in 32 studies that were included as part of the systematic 
review (Figure 1). Overall, there were 18 studies (56%) which were designed as primary 
prospective analyses of frailty in CKD. The remaining 14 studies (44%) were secondary analysis of 
established cohorts not originally sampled for examining frailty. 
 
Demographics of the Study Population 
Fifteen studies examined frailty in pre-dialysis patients with CKD, fourteen in the dialysis 
population and three in patients who had received kidney transplantation. These studies examined 
frailty in a total of 36 076 participants with CKD (82% in pre-dialysis patients and 18% in dialysis 
patients). The study characteristics and population demographics are reported in Tables 1 and 2.  
 
Critical Appraisal of Quality 
The average EAI score for the studies was 1.63 (Standard deviation – 0.18). The individual scores 
for each article are reported in Table 1 and 2. Overall, the articles performed well in describing the 
aims and defining the exposure and outcome variables. However, most articles did not publish 
sample size calculations, participation rates or account for subjects lost to follow up – these criteria 
were three lowest achieved amongst those of the EAI.  
 
Method of Frailty Assessment 
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The majority of studies classified frailty using the Fried phenotype (n=23, 72%). However, there 
were variations in the interpretation of the five characteristics of frailty compared to the original 
definitions stipulated by Fried et al (Table 3).2  
Estimation of physical activity and exhaustion showed the most heterogeneity between the studies. 
The most common methods of physical activity assessment were estimation of kilocalories (n=9, 
41%), patient self-report (n=8) and questionnaire based assessment (n=6). Exhaustion was 
determined most frequently by patient self-report (n=11, 48%), Short-Form 36 vitality score (n=6) 
and the Centre for Epidemiological Studies Depression Scale (n=5). Grip strength was the most 
common method of assessing weakness (n=14, 61%), whilst slowness was measured using timed 
gait speed (n=17, 74%). Shrinkage was estimated by measuring weight loss over 12 months (n=12, 
52%).  
There were seven studies (30%) that modified the Fried criteria for frailty and substituted the 
measurement of grip strength and gait speed for questionnaire based assessments of physical 
function. This method improves the feasibility of investigating frailty in large sample populations.11 
However, Painter et al12 showed that using questionnaire based data over-estimated the reported 
prevalence of frailty in haemodialysis patients. 
Ten studies (31%) employed a different measure to the Fried phenotype for frailty assessment. The 
most common of these, used in three studies, was the Clinical Frailty Scale. This is a clinical 
assessment of frailty developed from the Canadian Study of Health and Aging, which ranks fitness 
from a score of 1 (Very fit) to a score of 8 (severely frail and unlikely to recover from a minor 
illness) to a score of 9 (terminally ill).13 Other scales used include the frailty index approach, which 
provides a quantitative assessment of frailty as the proportion of potential deficits in health.4 This 
has been shown to be reproducible and be predictive of outcomes.14 Chao et al uses the FRAIL 
scale (Fatigue, Resistance, Ambulation, Illness, Loss of weight), which is related to the criteria 
developed by Fried et al but adds co-morbidity (illness) to self-reported assessment of the other 
criteria.15  Other measures used in the studies include the Groningen Frailty Indicator, Montesanto 
approach, Edmonton Frail Scale and a frailty check list.16-19  
 
Prevalence of Frailty 
Frailty was prevalent in patients with CKD, particularly in those on dialysis. Amongst the pre-
dialysis population the prevalence of frailty ranged from 7%, in a study of community dwellers with 
CKD (median estimated glomerular filtration rate (eGFR) = 49mLs/min), to 42.6% in a smaller 
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study of patients with more severe CKD (mean eGFR = 27mLs/min).20,21 A study by Rodriguez et 
al22 had no patients who were frail, despite the sample population having severe CKD (mean eGFR 
=16). However, patients in this study were referred into the clinic for consideration for dialysis; as a 
consequence of this screening process, only those who were ‘fit’ were selected.22   
Frailty was more prevalent amongst patients on haemodialysis with the range being from 14% to 
73%.23,24 There was no statistical comparison performed of the prevalence between dialysis and pre-
dialysis patients because of the differences in the methods used to assess frailty.  
 
Glomerular Filtration Rate and Frailty 
Six studies demonstrated a negative correlation between eGFR and the risk of frailty in pre-dialysis 
patients with CKD.20,25-29 Three of the six studies used cystatin C to estimate eGFR, two used 
creatinine and one use iodine 145-iothalamate clearance. A study by Roshanravan et al25 found that 
the relationship between frailty and CKD was attenuated when using creatinine instead of Cystatin 
C to estimate GFR. In five studies, there was significant increase in the risk of frailty with eGFR 
less than 45mLs per minute.20, 25-28 In the remaining study, only patients with an eGFR less than 
30mLs per minute were at a statistically significant increased risk of frailty because those with an 
eGFR >45 was used as the reference population.29    
A study by Dalrymple et al27 in the Cardiovascular Health Study cohort showed that CKD was 
associated with an increased risk of incident frailty. Patients with CKD who did not have baseline 
frailty were followed for four years. The risk of developing frailty was inversely related to baseline 
eGFR.27 Patients with a eGFR between 15 and 45 mls/min were twice as likely to develop frailty 
over four years when compared with patients with normal eGFR.27    
 
Mortality, Hospitalization and Falls 
Eight studies assessed adverse health outcomes in frail patients with CKD: four in dialysis 
populations and four in pre-dialysis cohorts. Johansen et al30 examined frailty in dialysis patients 
and found an increased risk of death associated with frailty after one year of follow-up (Hazard 
Ratio [HR] 2.24, 95% CI 1.6 – 3.15). Similarly, Bao et al23 and McAdams De-Marco et al31 
reported a significant risk of mortality associated with frailty amongst the dialysis population. The 
relationship between frailty and risk of death persisted after multivariate adjustment for age, sex and 
co-morbidities in all three studies. Alfaadhel et al32 demonstrated that each one point increase in the 
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Clinical Frailty Scale was associated with an increased risk of mortality in haemodialysis patients 
(HR 1.22 [95% CI 1.04-1.13]; median follow-up: 1.7 years). Bao et al23 and McAdams De-Marco et 
al31 also demonstrated that frailty correlated with an increased risk of hospitalization in dialysis 
patients. An analysis of a composite end-point of death or hospitalization reached statistical 
significance in the study by Johansen et al (HR 1.56 95% CI 1.36-1.79).30      
Roshanravan et al25 conducted a study in patients with CKD stages 1-4 and demonstrated that frailty 
was an independent risk factor for death or progression to dialysis (HR: 2.5 [95% CI 1.4-4.4]; 
median follow-up: 2.6 years). In a study by Wilhelm-Leen et al26, frailty increased the risk of death 
in patients with CKD and the risk was only partly attenuated in a multivariate model that adjusted 
for co-morbidities, inflammation and sarcopenia (HR 2.0 [95% CI 1.5 – 2.7]). Studies by Delgado 
et al29 and Pugh et al33 also demonstrated an increased risk of mortality in patients with pre-dialysis 
CKD who were frail.  
Frailty is a risk factor for falls in patients with end stage kidney disease In a cohort of haemodialysis 
patients, McAdams De-Marco et al34 demonstrated that frailty increased the risk of falls by three 
times compared to those who were not frail (RR=3.09, 95% CI 1.38 – 6.90).   
 
Frailty and the Kidney Transplant Recipient 
Three studies have investigated frailty in kidney transplant recipients. McAdams De-Marco et al35 
demonstrated that incident frailty increased the risk of hospital readmission amongst kidney 
transplant recipients (Relative Risk= 1.61, 95% CI 1.18-2.19). This risk persisted after adjustment 
for age, gender, co-morbidity, time spent on dialysis and donor factors. Another study by Garonzik-
Wang et al36 showed that frailty was an independent risk factor for delayed graft function 
(RR=1.94, 95% CI 1.13-3.36). A second study by McAdams De-Marco37 investigated the change in 
frailty status after kidney transplantation. It found that the prevalence of frailty in the cohort 
decreased at 3 months of follow up and that patients who were frail before transplantation were 
twice as likely to have improvement in frailty score after transplantation (HR: 2.55 [95% CI: 1.71-
3.82]).37 
 
Discussion  
In this systematic review of frailty in patients with CKD, the prevalence of frailty increased with 
poorer kidney function and was highest in patients receiving dialysis.  Frailty was a significant 
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predictor of adverse health outcomes, particularly in those with severe CKD stages. However, we 
found differences in frailty assessment and estimation of GFR and this may have influenced the 
reported prevalence of frailty.  
The Fried phenotype provided the basis for frailty assessment in the majority of the studies in this 
review (n=23, 72%). This is a well validated method of frailty assessment that classifies patients as 
frail, pre-frail or not frail categories.2 However, the Fried phenotype is less useful in grading the 
severity of frailty in populations where the prevalence of frailty is high.38 This is particularly 
problematic in patients on dialysis with one study demonstrating the prevalence of frailty be as high 
as 73%.23 Other methods, such as the frailty index, provide a continuous variable that may improve 
the discrimination of those patients at high risk, especially in patients on dialysis.39      
The feasibility of using performance based tests of grip strength and slowness has proven to be 
problematic in retrospective studies that have used the Fried phenotype. One approach, proposed by 
Woods et al11, involves replacing performance based tests with questionnaire based data to grade 
loss of physical function.  However, the correlation between measuring grip strength and slowness 
versus estimating physical function using the SF-36 questionnaire is poor (r=-0.34 for gait speed; 
r=0.14 for grip strength).11 There were seven studies that modified the Fried phenotype and used the 
approach of using questionnaire data to replace the measured variables12,21,23,39,30,40,41. Subsequently, 
Painter et al12 conducted a comparison of measuring gait speed and grip strength versus 
questionnaire data in quantifying the prevalence of frailty in haemodialysis patients. The study 
found the prevalence of frailty was 24% in the performance based group and 78% in the group 
using questionnaire data.12 Thus the methods by which the characteristics of Fried’s phenotype of 
frailty are defined can considerably influence the prevalence of frailty in the population being 
investigated.  
GFR estimation was different amongst the studies and this may influence the relationship between 
frailty and severity of CKD. The most common method of deriving an eGFR is by creatinine 
clearance, as reported in 12 studies. However, since this relies on muscle mass, the eGFR of frail 
patients who have lost muscle mass may be over-estimated. Another method of estimating GFR is 
by using cystatin C which is not influenced by muscle mass and this was utilised in three studies. 
The strength of the association between frailty and eGFR appears to be increased by using cystatin 
C.  
Regardless of the method of estimation, GFR seems to be an important mediator in the risk of 
frailty in patients with CKD. Five studies demonstrated that eGFR less than 45mLs/min was 
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associated with increased odds of frailty.20, 25-28 There were differences in the calculation of the 
odds ratios because of different definitions of the eGFR of the reference population. This influenced 
the value of the odds ratios and prevented comparisons between studies.  
The prevalence of frailty ranged from 7% to 42.6% in pre-dialysis patients.20,21 Amongst dialysis 
patients, the highest prevalence of frailty in the studies analysed was 73%.23  However, there was a 
wide range of frailty prevalence in the various CKD populations included in this review. 
Differences in the demographics of the study population, average eGFR, gender, co-morbidities and 
ethnicity may explain this difference. Furthermore, as demonstrated previously, the method of 
frailty assessment can considerably influence the proportion of patients classified as being frail.   
Patients with CKD who were frail were at increased risk of mortality and hospitalization. The risk 
of mortality was significant in both dialysis and pre-dialysis patients with CKD.23,25,26,29-33 Frailty 
also predicted an increased risk of falls in patients with CKD.34,42 In the kidney transplant recipient, 
frailty was associated with an increased risk of early hospital readmission and delayed graft 
function.35,36 Patients who were frail prior to transplantation were also more likely to have 
improvement in frailty after transplantation.37 A previous systematic review by Walker et al9 found 
similar associations between frailty and adverse health outcome in patients with non-dialysis CKD. 
The association of frailty with mortality risk is consistent with other studies in community dwellers 
with normal renal function.5,11  
The findings of this systematic review have multiple implications for clinical practice. Firstly, it 
highlights the prevalence of frailty particularly in those with Stage 5 CKD and those on dialysis. 
Identifying these patients is important because frailty is associated with poor health outcomes. 
Frailty is a useful marker of health status and can be used to monitor response to interventions; an 
example of this can be seen in the study by McAdams de Marco and colleagues who explored how 
frailty status changed before and after kidney transplantation.37   
Whilst a number of the articles in this systematic review were primary prospective studies, there is 
little data commenting on the length of time to complete these frailty assessments or the resources 
needed. One study, investigating the frailty index, demonstrated that a frailty assessment is feasible 
in an outpatient CKD clinic and could be conducted in approximately 10 minutes using a 
questionnaire.39 However, there is a need to compare different frailty assessment methods to 
establish which is better suited in a clinical setting. With the exception of kidney transplantation, 
there is no evidence for interventions that can change a patient’s frailty status if they have CKD. 
Frailty manifests when there is a critical number of deficits across multiple systems including those 
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that regulate inflammation.7 Thus, it is likely that multiple strategies will be needed in tackling this 
issue of frailty in patients with CKD.  
There are strengths and limitations inherent in this systematic review. It encompasses a diverse 
range of populations with CKD including patients on dialysis, community dwellers who are not on 
dialysis and kidney transplant recipients. The total sample size is large with 36,000 patients.  
However, differences in the method of frailty assessment and estimation of GFR between the 
studies meant there was considerable heterogeneity between studies. For this reason, a meta-
analysis and summation statistics could not be performed to take full advantage of the large sample 
size. A large proportion of studies (n=14, 44%) used a secondary analysis in an existing cohort of 
patients to examine the relationship between frailty and CKD. This raises issues of external validity 
and whether the studies sufficiently addressed selection bias when presenting the findings. 
Unpublished results and a single article not available in the English language were excluded from 
this systematic review. Publication bias is a possibility because of exclusion of these studies.  
 
Conclusion 
Based on the number of studies, consistency and quality of the findings, there is strong evidence 
that frailty is associated with CKD and that patients with more severe CKD are more likely to be 
frail. Frailty predicts poor outcomes in patients with CKD including an increased risk of mortality 
and hospitalization. There is a need to better understand causality and why frailty is associated with 
adverse health outcomes in patients with CKD. Further research should also explore different 
methods of frailty assessment that better delineate those who are most frail and who may benefit 
from targeted intervention.  
 
 
Appendix 2:  Participant Information 
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Non-Interventional Study 
 
Princess Alexandra Hospital 
 
 
Title Clinical Utility of the Frailty Index in CKD patients 
Short Title Frailty in Chronic Kidney Disease 
Protocol Number Version 3 June 2014 
Project Sponsor Nil 
Coordinating Principal Investigator/ 
Principal Investigator 
Dr Ruth Hubbard 
 
Associate Investigator(s) 
 
Dr Nancye Peel 
Mr Rakin Chowdhury 
Location Nephrology Outpatient Department 
 
 
 
Part 1 What does my participation involve? 
1 Introduction 
 
You are invited to take part in this research project, Frailty Index in Chronic Kidney 
Disease. We are investigating the measurement of frailty in outpatients with chronic kidney 
disease at the Princess Alexandra Hospital. 
 
This Participant Information Sheet tells you about the research project. Knowing what is 
involved will help you decide if you want to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or local doctor. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. You 
will receive the best possible care whether or not you take part. 
 
If you decide you want to take part in the research project, you will be asked to sign the 
consent section. By signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information to keep and the consent form can be 
made available to you should you request it.
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2  What is the purpose of this research? 
 
Many people with chronic kidney disease remain fit and active. Some people have other 
diseases and develop problems with their overall health. Frail is a term used in medicine to 
describe these vulnerable people. Frailty does not have a precise meaning but ‘frail’ patients 
have sometimes lost weight, become weaker and able to exercise less or have problems with 
their memory. Frailty is important because people who become frail often do less well than 
other people and need more care from relatives and medical services. 
 
It is not known why some people become frail and others do not. It may be the result of a 
combination of changes in the body due to age or illness. For example, muscles tend to waste 
in frail people and they tend to lose muscle strength. Some things seem to slow down like the 
production of blood cells or the body’s ability to break down medicines. It is likely to be a 
combination of all these factors. 
 
We are carrying out a study in the Princess Alexandra Hospital, looking at how we can 
measure frailty in people with chronic kidney disease. We think that by asking questions 
about different aspects of health (medical problems, ability to look after yourself, mood, sleep, 
thinking) we can work out how frail a person is. 
 
We would like to include you in the study. This does not mean that we think that you are frail. 
We are trying to test if the measurement instrument works so want to include a whole range 
of people – from those who are very fit to those who are very frail. 
 
 
3 What does participation in this research involve? 
 
If you consent to taking part in the study, we will ask you some questions about your medical 
history and medications. You will also be asked about your memory, quality of life and current 
level of functioning, for example whether you are able to wash and dress yourself 
independently. The questions take about 10 minutes to answer. We would also like to 
contact you by telephone in 12 months for a follow-up. We would like to ask you some 
questions about whether your level of functioning has changed and if you have had any 
admissions into hospital. These questions would take 5 minutes to answer. 
 
Please note there are no costs associated with participating in this research project, nor will 
you be paid. The research project has been designed so that the researchers interpret the 
results in a fair and appropriate way. We would also appreciate it if you provide a contact 
number for the follow up in 12 months. Your contact details will be kept confidential and will 
only be used for the purposes of this research. 
 
 
4 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you do not 
have to. If you decide to take part and later change your mind, you are free to withdraw from 
the project at any stage. 
 
If you do decide to take part, you will be given this Participant Information. The Consent Form 
will be made available from the Centre for research in Geriatric Medicine should you wish to 
access it. 
 
Your decision whether to take part or not to take part, or to take part and then withdraw, will 
not affect your routine treatment, your relationship with those treating you or your relationship 
with Princess Alexandra Hospital Nephrology Department.
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5 What are the possible benefits and risks of taking part? 
 
Whilst there will be no clear benefit to you from you participation in this research the 
information that you provide will help us show how frailty impacts the health of patients with 
chronic kidney disease. This research does not involve any interventional treatment you will 
be receiving routine medical care. As such we do not anticipate any risk to you from taking 
part in this interview. 
 
 
6 What if I withdraw from this research project? 
 
If you decide to withdraw from this research project, please notify a member of the research 
team before you withdraw. 
 
If you do withdraw your consent during the research project, the study researcher and 
relevant study staff will not collect additional personal information from you, although personal 
information already collected will be retained to ensure that the results of the research project 
can be measured properly and to comply with law. If you do not want them to do this, you 
must tell them before you join the research project. 
 
 
7 What happens when the research project ends? 
 
You will be provided with usual clinical care during the course of the research project and 
after it ends. The results of the project will be made available to you via the Centre for 
Research in Geriatric Medicine (University of Queensland). 
 
 
 
Part 2 How is the research project being conducted? 
8 What will happen to information about me? 
 
By signing the consent form you consent to the study researcher collecting and using 
personal information about you for the research project. Any information obtained in 
connection with this research project that can identify you will remain confidential. All 
electronic data will be kept in a password protected database. Any identifiable material will be 
kept securely under lock and key. Your information will only be used for the purpose of this 
research project and future approved research projects and it will only be disclosed with your 
permission, except as required by law. 
 
Any personal information will remain confidential and you will be de-identified as part of the 
analysis of this study. All data will be disposed of securely in seven years at the end of the 
storage period. 
 
This research forms part of a larger investigation into frailty in different patient populations. 
The information you provide may be used in further studies for this purpose. 
 
Information about you may be obtained from your health records held at this and other health 
services for the purpose of this research. By signing the consent form you agree to the 
research team accessing health records if they are relevant to your participation in this 
research project. 
 
It is anticipated that the results of this research project will be published and/or presented in a 
variety of forums. In any publication and/or presentation, information will be provided in such 
a way that you cannot be identified.
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In accordance with relevant Australian privacy laws, you have the right to request access to 
the information collected and stored by the research team about you. You also have the right 
to request that any information with which you disagree be corrected. Please contact the 
research team member named at the end of this document if you would like to access your 
information. 
 
 
9 Who is organising and funding the research? 
 
This research project is being conducted by The Centre for Research into Geriatric Medicine 
(University of Queensland) and the Princess Alexandra Hospital Nephrology Department. 
 
 
10 Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people 
called a Human Research Ethics Committee (HREC).  The ethical aspects of this research 
project have been approved by the HREC of Princess Alexandra Hospital (Metro South). 
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007). This statement has been developed to protect the interests of 
people who agree to participate in human research studies. 
 
 
11 Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query. If you have any 
concerns or complaints about the study please do not hesitate to contact the person listed 
below. 
 
 
Study Contact person 
 
 
 
If you have any complaints about any aspect of the project, the way it is being conducted or 
any questions about being a research participant in general, then you may contact: 
 
 
Reviewing HREC approving this research and HREC Executive Officer details 
 
Name Dr Ruth Hubbard 
Position Consultant Geriatrician, Senior Lecturer (UQ), Principal Investigator 
Telephone 3176 5530 
Email crgm@uq.edu.au 
Reviewing HREC name Metro South HREC 
Telephone 3443 8049 
Email EthicsResearch.PAH@health.qld.gov.au 
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Consent Form - Adult providing own consent 
 
Title Clinical Utility of the Frailty Index in CKD patients 
Short Title Frailty in Chronic Kidney Disease 
Protocol Number Version 3 June 2014 
Project Sponsor Nil 
Coordinating Principal Investigator/ 
Principal Investigator 
Dr Ruth Hubbard 
 
Associate Investigator(s) 
 
Dr Nancye Peel 
Mr Rakin Chowdhury 
Location Nephrology Outpatient Department 
 
Declaration by Participant 
I have read the Participant Information Sheet or someone has read it to me in a language that 
I understand. 
I understand the purposes, procedures and risks of the research described in the project. 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
 
I freely agree to participate in this research project as described and understand that I am free 
to withdraw at any time during the project without affecting my future health care. 
 
I understand that I will be given access to this document if I should request it. 
 
I give permission for my doctors, other health professionals, hospitals or laboratories outside 
this hospital to release information to The Centre for Research in Geriatric Medicine 
concerning my condition and treatment for the purposes of this project. I understand that such 
information will remain confidential. 
 
A member of the research team may request my permission to obtain access to my medical 
records for collection of follow-up information for the purposes of research and analysis. 
 
 
 Name of Participant (please print)     
 
 Signature  Date   
 
 
Declaration by Study Researcher† 
I have given a verbal explanation of the research project, its procedures and risks and I 
believe that the participant has understood that explanation. 
 
 
 Name of Study Researcher 
(please print) 
  
  
 Signature  Date   
 
 
Note: All parties signing the consent section must date their own signature. 
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Appendix 3 Frailty Assessment Form 
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Appendix 4: Ethics Approval Form 
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Appendix 5: Abstract Prospective Study 
Background: Frailty can be conceptualized as an accumulation of deficits across 
multiple systems in an approach known as the frailty index (FI). FI has been validated 
in a number of patient populations and it correlates with health outcomes including 
mortality and hospitalization. Previous literature has shown patients with chronic 
kidney disease (CKD) have a high prevalence of frailty. However, there is a need to 
better delineate risk amongst this population and understand how frailty changes with 
kidney function and dialysis status. 
Aim: The aim of the FI-CKD study is to investigate the FI and its association with 
kidney function and dialysis status. Secondary outcomes include the association of 
frailty with mortality and hospitalization in patients with CKD. 
Methods: Outpatients from nephrology clinics and dialysis centres were recruited in 
two study settings between August 2013 and January 2015.  A previously validated 
method using a structured interview and frailty assessment form was used to collect 
data to calculate the FI. The patients’ medical records provided information about co-
morbidity and kidney function (estimated with serum creatinine).  A follow up of 
health records was conducted 12 months after recruitment to record mortality and 
hospitalization data. Ethics boards at the corresponding recruitment sites approved the 
FI-CKD study. 
Results: There were 314 participants recruited and 42% (n=132) were female. The 
average age was 64 years (SD 13 years) with the majority having pre-dialysis CKD 
(n=228, 73%). The average FI for the sample was 0.29 (SD 0.13), which corresponds 
to mild to moderate frailty.  There was no significant difference in frailty between 
patients on dialysis to those pre-dialysis (p=0.52). FI correlated with CKD stage even 
after adjustments for age and co-morbidity on ordinal regression analysis (p<0.05).   
For each 0.1 unit increase in FI, there was a 1.8 fold increased risk of death (95% CI 
1.77 – 2.44). FI also correlated with an increased risk of hospitalization (OR 1.3 95% 
CI 1.06-1.5). 
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Conclusion: Patients with CKD have a significant burden of frailty. Kidney function 
was associated with FI; patients with higher CKD stage were more likely to have a 
higher FI and be frailer. However, there was no significant difference in FI between 
pre-dialysis and dialysis patients, perhaps due to a lack of statistical power or due to 
selection bias. FI was strongly associated with an increased risk of morality and 
hospitalization. 
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